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Abstract 
The blood-brain-barrier (BBB) is the single most limiting factor in the delivery of 
neurotherapeutics into the brain. Focused ultrasound sonication combined with intravenous 
microbubble administration (FUSwMB) is a novel technique that can transiently disrupt the 
BBB, with minimal vascular or tissue damage, allowing for localized drug delivery over the 
targeted region. The goals of this thesis are to: 1) use computed tomography (CT) perfusion 
to measure the permeability surface area product (PS) following FUSwMB in normal rabbits 
with an intact BBB, and 2) to evaluate the blood-tumor-barrier (BTB) PS response following 
FUSwMB in a C6 rat glioma model. 
Chapter 2 evaluated CT perfusion as a tool for monitoring and measuring the increased PS 
following FUSwMB induced BBB disruption. A range of exposure parameters, power and 
sonication time, were evaluated to induce transient BBB disruption with minimal injury, in a 
rabbit model. The PS vs. time profile showed a distinct window for increased drug delivery 
following FUSwMB, and can be used to predict delivery over the targeted region.  
Chapter 3 evaluated CT perfusion derived BTB PS response acutely over 4 hours, and sub-
acutely over 3 days, using both small (760 Da) and large molecular (65 kDa) weight CT 
contrast agents, following FUSwMB in a C6 rat glioma model. The BTB PS measured with 
standard small contrast agent, which was abnormally elevated at baseline because of the 
breakdown of the BBB in tumor vasculature, demonstrated a gradual decrease up to 4 hours 
following sonication, and remained decreased at 24 hours post. The BTB PS measured with 
the larger contrast agent showed an increasing trend at 24 hours post FUSwMB, when the 
Isovue PS was at its lowest.  
Chapter 4 investigated the CT Perfusion derived extravascular distribution volume (Ve), as a 
surrogate of vasogenic edema, following FUSwMB in the rat C6 glioma model as in Chapter 
3. The decrease in Isovue PS at 24 hours post FUSwMB was accompanied by a decrease in 
Ve, implying a decrease in vasogenic edema and also the abnormally elevated interstitial fluid 
pressure (IFP). The results of Chapter 4 suggested a mechanism for the observed decrease in 
Isovue BTB PS following FUSwMB in Chapter 3 and its implications on drug delivery in 
  
brain tumors. It is hypothesized that the destruction of newly formed vessels from 
angiogenesis or the stimulation of reactive glial cells following FUSwMB were responsible 
for normalizing the BTB PS, thereby lowering IFP and improving perfusion and 
transvascular drug delivery throughout the tumor. 
Chapter 5 summarized the findings indicating CT Perfusion can be used to monitor the 
change in BBB/BTB PS following FUSwMB. In the disrupted BBB, when PS is 5 times less 
than blood flow (F), PS can be used to approximate drug delivery, however, when PS is 
significantly elevated, as with brain tumors, the volume transfer constant (FE) is the correct 
functional parameter and should be used instead. Future studies investigating the 
improvement in delivery and clinical outcomes for larger chemotherapeutic drugs, such as 
bevacizumab, following FUSwMB are also presented.  
Keywords 
Focused ultrasound, microbubbles, sonication, blood-brain-barrier, blood-tumor-barrier, CT 
perfusion, permeability surface area product, volume transfer constant, drug delivery. 
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Chapter 1  
1 Introduction 
1.1 Overview 
The blood-brain-barrier (BBB) is made up of endothelial tight junctions and associated 
anatomical structures including the basement membrane, astrocyte foot processes, and 
pericytes. It is important for maintaining homeostasis in the brain by tightly regulating 
neurovascular exchange at the endothelium. Only small lipophilic molecules (<500 Da) 
are able to freely diffuse across the BBB, meaning that the vast majority of intravenously 
delivered drugs never make it into the brain. As a result, it is widely acknowledged that 
the BBB is the single most limiting factor in the delivery and development of 
neurotherapeutics. Recently, it has been demonstrated that the combined use of focused 
ultrasound (FUS) and intravenously injected microbubbles (MB) is able to non-invasively 
and transiently disrupt the intact BBB, allowing for the localized delivery of a range of 
molecules, from small chemotherapeutic agents, to large antibody based drugs, and even 
nanoparticles. In brain tumors, such as glioblastoma multiforme (GBM), the permeable 
blood-tumor-barrier (BTB) presents its own challenges in drug delivery due to the build 
up of interstitial fluid pressure in and around the tumor. For the clinical translation of 
such a promising drug delivery strategy - it is important to identify vascular parameters 
that can be used to monitor the exchange of drug between blood vessels and tissue, and 
predict delivery following FUS sonication with MB administration (FUSwMB). 
Computed Tomography (CT) Perfusion is a quantitative and functional imaging 
technique that lets us serially evaluate vascular parameters such as cerebral blood flow 
(CBF), cerebral blood volume (CBV), and most importantly for this application – 
permeability surface area product (PS), which approximates the unidirectional flux of 
blood solutes into tissue. This thesis focuses on using CT Perfusion to quantify the 
changes in PS following FUSwMB in pre-clinical models, and how these changes relate 
to drug delivery in the normal intact BBB, and across the BTB in a rat glioma model. 
This introductory chapter provides an overview of the basic biology and physiology of 
the BBB and BTB, the mechanisms and current literature for mediated drug delivery 
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studies with and without FUSwMB, the imaging techniques that will be used in our 
investigation, followed by an outline of this thesis.  
1.2 Blood-Brain-Barrier (BBB) 
The BBB consists of a series of endothelial tight junctional complexes and associated 
structures which among other functions, regulate the permeability of solute exchange 
between the blood and brain tissue (1). These endothelial complexes and structures, each 
consisting of endothelial cells with proteins sealing the gaps between them, basement 
membrane, astrocytic foot processes, pericytes, and microglia, together with neurons 
form the neurovascular unit (2). A schematic of a cerebral capillary cross sectional is 
shown in Figure 1-1. Attached to the abluminal surface of the endothelium are connective 
tissue cells known as pericytes (3,4). The pericytes and the endothelium are then 
surrounded by the basal lamina, which is 30 to 40-nm thick membrane comprised of a 
number of connective tissues and extracellular matrix proteins (5). Contiguous with the 
basal lamina, is the plasma membrane of astrocytes, which ensheathes cerebral capillaries 
and serve many physiological functions regulating the vasculature and neuronal cells 
(6,7).  
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Figure 1-1: Schematic cross-sectional representation of a cerebral capillary, 
highlighting a single endothelial cell (EC), the tight junctions (TJ), pericytes (PC), 
basal lamina (BL), and astrocytes (AC). Adapted from Hawkins et al 2005 (8). 
Functions of the BBB in the neurovascular unit include: 1) maintaining central nervous 
system (CNS) homeostasis, 2) isolating the brain from other body compartments, 3) 
providing a constant supply of oxygen and nutrients by specific transport systems, and 4) 
directing inflammatory cells in response to changes in the local environment (2,9).  
These physical and transport barriers work together to maintain and regulate BBB 
permeability. Since no brain cell is more than 25 µm from basement membrane of the 
BBB, and the endothelial cytoplasm at the abluminal surface of the BBB spans 200-
300nm, the BBB is an ideal target to enhance the delivery of drugs into the brain. (10).  
1.3 Drug Delivery across the BBB 
Around 98% of all small molecules are not able to cross the BBB, and into the brain 
insterstitium (11). A comprehensive review of over 6000 drugs found that only 1% were 
delivered and demonstrated activity in the CNS (12). The absence of para-cellular or 
trans-cellular channels that are seen in other endothelium throughout the body means that 
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molecules in the vasculature may only cross the BBB via one of two mechanisms: 1) Free 
diffusion of lipid soluble molecules, typically with a molecular mass of less than 500 Da, 
through the lipid bilayer of the endothelium, and 2) carrier- or receptor- mediated 
transport (CMT or RMT) through the barrier.  
CMT is facilitated by diffusion of certain solutes across the BBB. The solute binds to a 
transporter on one side of the BBB, triggering a conformational change in the carrier 
protein, resulting in a transfer of solute across the barrier, from high to low concentration. 
CMT contributes to the transport of small molecules such as small peptides, glucose, 
amino acids, and monocarboxylates (13). RMT occurs via bulk- or fluid-phase 
endocytosis and provides a means to transport macromolecules into the CNS. Although 
fluid-phase endocytosis is relatively non-specific, RMT is highly selective and occurs to 
a very limited degree across the BBB for certain ligands, hormones, growth factors, 
enzymes, and plasma proteins (14). Endogenous RMT systems can also allow for the 
reengineering of recombinant proteins or peptides using molecular Trojan horses to 
develop pharmaceuticals that can penetrate the BBB (15). Although CMT and RMT are 
promising techniques for drug development and delivery across the BBB, their 
effectiveness is often limited and can benefit in conjunction with other approaches to 
circumvent the barrier (16). 
One strategy for the reversible disruption of the BBB is by the intracarotid arterial 
infusion of agents such as mannitol (17), vasoactive agents (18), solvents (19), alkylating 
agents (20), immune adjuvants (21), cytokines (22), and other miscellaneous agents (23). 
The major limitation of these techniques is the non-localized disruption of the BBB, 
which can increase neuronal toxicity from the drug delivered (24). More-invasive neuro-
surgical transcranial drug delivery techniques such as: 1) intracerebral implantation (25), 
2) intracerebroventricular infusion (ICV) (26), or convection enhanced diffusion (CED) 
(27) are also used when justified because of the risk associated with surgery. The first 
two approaches involve direct injection of the drugs into the brain and ventricles and 
subsequent diffusion into neighboring brain tissue, whereas CED forces drug containing 
fluid into the brain against the concentration gradient.  
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1.4 Malignant Gliomas 
More than 20,000 North Americans are diagnosed annually with primary malignant brain 
cancers (28). Gliomas, which represent the majority of brain tumors, are derived from 
glial cells that maintain the BBB homeostasis as well as other functions in the central 
nervous system (29,30). They are divided into astrocytic and oligodendroglial subtypes, 
and are classified as grades I to IV based on their growth rates (31). High-grade or 
malignant gliomas, which account for approximately 70% of all malignant brain tumors, 
have particularly poor prognosis (32). Glioblastoma multiforme (GBM), characterized by 
increased mitotic activity, proliferation of the microvasculature, and necrosis, is the most 
severe grade, with median survival between 12 to 15 months (31). 
Because of their neovascular and infiltrative nature, GBM treatment may vary based on 
the type, location, and grade of the tumor, and involves combination of debulking surgery 
when possible, followed by chemotherapy and/or radiation (33).  Surgical resection to 
palliate symptoms and improve function when feasible is the first line standard of care, 
followed by 40 to 60 Gy fractionated radiotherapy and concurrent Temozolomide at a 
dose of 75 mg/m2 per day, beginning within six weeks of surgery. Following this 
concurrent treatment, cycles of adjuvant chemotherapy cocktails can be administered for 
improved outcomes, with risk of side affects being a limiting factor. 
Adjuvant Temozolomide chemotherapy is commonly combined with carmustine, a 
mixture of procarbazine, lomustine, and vincristine (34), or more recently, bevacizumab 
(35,36). However, recent phase 3 clinical trials suggest that these chemotherapy cocktails 
provide a limited response, prolonging progress free or overall survival by only a matter 
of months (37,38). In addition, the risk of systemic toxicity often limits the administered 
dose and effectiveness of the treatment (39). 
1.4.1 Blood-Tumor-Barrier 
When a primary brain tumor grows beyond 1-2 mm in diameter within the brain 
parenchyma, the BBB becomes structurally and functionally compromised (40–42). As 
the tumor continues to grow and infiltrate into surrounding normal brain, other 
pathological features include marked angiogenesis and endothelial proliferation, tissue 
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hypoxia, and eventually tumor necrosis also arise (43–45). In high grade gliomas, vessels 
become tortuous, disorganized, highly permeable, and are characterized by abnormalities 
in their endothelial wall, basement membrane, and pericyte coverage (46,47), as seen in 
Figure 1-2. In patients and pre-clinical models, tumors as compared to normal vessels 
also have structurally abnormal and significantly larger diameters and thicker basement 
membranes (48,49).  
	  
Figure 1-2: Photomicrograph of (a) normal mice brain vasculature, and (b) a glioma 
xenograft in an immnodeficient mouse brain. The normal vasculature is optimally 
organized, appropriately connected and shaped to provide nutrients to all 
parenchymal cells, whereas the cancer vasculature is disorganized, poorly 
connected, and tortuous.  Adapted from Jain et al. 2007 (50). 
The structural abnormalities present in the BTB also lead to abnormal function, 
characterized primarily by the increase in vascular permeability. Although some BBB 
function is retained, evident by the reduced transvascular transport in intracranial tumors 
compared to subcutaneous ones (41,51), brain tumor vessels contain endothelial pores as 
large as 550 nm in diameter (52). It’s important to note that the loss of BBB integrity is 
not uniform, but temporally and spatially heterogeneous as tumors progress (53). The 
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heterogeneous leakiness of brain tumor vessels cause abnormal blood flow, which leads 
to abnormal delivery of oxygen, leading to hypoxia, as well as the spatially and 
temporally heterogeneous delivery and distribution of blood-borne drugs throughout the 
tumor (54).  
The abnormal BTB permeability is also accompanied by other pathophysiological states 
in the tumor microenvironment, including accumulated solid stress (55–58), elevated 
interstitial fluid pressure (54,59–61), and a dense interstitial structure (62–64). These 
abnormalities contribute to variable avascular regions, sluggish and non-uniform 
perfusion, diminished trans-vascular pressure gradients, and highly viscoelastic 
interstitial components that hinder drug penetration and delivery (65).  
1.4.2 Drug Delivery in Brain Tumors 
All systematically administered cancer therapeutic agents must follow a long and 
complex journey from the point at which it enters the circulation, up until it reaches its 
target (65,66). There are three major transport processes that govern this delivery leading 
up to uptake by the target: 1) vascular transport, 2) transvascular transport, and 3) 
interstitial transport, as shown in Figure 1-3. In normal vasculature, these transport 
processes are highly efficient, effectively delivering oxygen and nutrients throughout the 
brain.  
Vascular transport is defined as the convective delivery of drugs into different regions of 
the tumor, driven by blood flow. It can be defined by the volumetric flow rate, Q, in 
blood vessels supplying the volume of tissue and is equal to the pressure drop (Δp) 
divided by the resistance of the blood vessels (R). The rate of drug delivery to the tumor 
is defined as the flux of drug Jv into a tissue region, which is equal to Q multiplied by the 
drug concentration in the feeding blood vessels Cv, or Jv = QCv.  
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Figure 1-3: Mechanisms of vascular, transvascular, and interstitial transport in a 
tumor tissue unit consisting of blood vessels and the surrounding tissue.   Adapted 
from Chauhan et al. 2011 (65). 
The net flux of drug delivery across the BBB is governed by the transvascular transport 
process. In the brain, transvascular flux of drug Jt, is a combination of diffusive flux Jd, 
and convective flux Jc. Jd is dependent on the difference between the plasma 
concentration Cb, and the interstitial concentration Ce, multiplied by the proportionality 
constants, vascular diffusive permeability Pd, and the vascular surface area Sv. 
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  𝐽𝑑 = 𝑃𝑑𝑆𝑣(𝐶𝑏 − 𝐶𝑒)    … Equation 1-1 
Similarly, Jc is calculated as, 
  𝐽𝑐 = 𝐿𝑡𝑆𝑣(1 − 𝜎𝑠)(∆𝑝! − 𝜎∆Π)   … Equation 1-2 
where Lt is the hydraulic conductivity across the BBB, Δp is the transmural hydrostatic 
pressure gradient, ΔΠ is the transmural osmostic pressure gradient pressure gradient, σ is 
the osmotic reflection coefficient, and σs is the solute’s reflection coefficient. 
The diffuse permeability, Pd, and hydraulic conductivity, Lt, are dependent on biophysical 
properties of the endothelium and basement membrane, including viscoelasticity and 
porosity, as well as physiochemical properties of the drug or drug carrier itself, including 
size, charge, and configuration.  
A major barrier for drug delivery in tumors is caused by the build-up of solid stress from 
uncontrolled proliferation of tumor cells. This also compresses lymphatic vessels which 
become unable to drain the tumor of accumulating fluid and plasma macromolecules in 
the tumor interstitium, leading to vasogenic edema (67). With no drainage and small to 
no transmural oncotic pressure difference, the interstitial fluid pressure (IFP) rises to the 
microvascular pressure, abolishing the transvascular pressure gradient required for 
convective transport across the BTB (66), as per Equation 1-2, and is shown in Figure 1-
4. 
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Figure 1-4: Interstitial fluid pressure profile in the subcutaneous rat tumor, 
indicating a sharp increase at the periphery and reaching a plateau within the core 
of the tumor. Adapted from Chauhan et al. 2011 (59). 
Since smaller molecules such as Temozolomide (214 Da) are able to diffuse across the 
permeable BBB/BTB, this increase in IFP is more problematic for the delivery of larger 
molecules that rely more heavily on convective transport through the permeable barrier. 
Convective transport is particularly of interest for delivery of monoclonal antibody based 
cancer therapeutics, such as Bevacizumab (149 kDa), and Trastuzumab (145 kDa) 
because of their large size.  
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1.5 FUS and MB induced BBB Disruption  
Recent advances in acoustic technology have opened the doors for a novel strategy to 
temporarily disrupt the BBB in targeted regions of the brain using pulsed FUS, allowing 
for increased endothelial permeability and therefore drug delivery (68–75). FUS 
concentrates acoustical energy in a small volume, with minimal effects to neighboring 
tissue, and can be used to non-invasively induce biological effects in the body. In the 
presence of intravenously injected gas-filled encapsulated MB, FUS can be used to trans-
cranially and reversibly disrupt the vasculature within the focal spot of the ultrasound 
transducer.  FUSwMB offers a means to effect non-invasive localized opening of BBB 
and hence delivery of small- or large- molecule drugs, allowing for the development of 
pharmaceuticals for brain tumors and most CNS disorders (76).  
The observed BBB effects from FUSwMB are predominantly due to cavitation, which is 
an acoustically induced oscillation of MB within the vasculature, resulting in sheer stress 
on the luminal surface of the capillary endothelium (77). 
	  
Figure 1-5: Proposed mechanisms which result in ultrasound induced blood brain 
barrier disruption in the presence of microbubbles: A) radiation forces, B) bubble 
oscillation, and C) acoustic streaming. Adapted from (76). 
In actual fact, the BBB effect may be attributed to a combination of cavitation, acoustic 
streaming, and radiation forces, as shown in Figure 1-5 (77). At relatively low acoustic 
pressure, MB oscillate within the ultrasound field, which is called “stable” cavitation. 
The biological effects, including disruption of the BBB, observed on vascular 
endothelium from stable cavitation can be mostly attributed to direct shear stress, and an 
A B C 
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eddying micro-streaming of the fluid resulting from the oscillating bubble (78–80). For 
the endothelium to be affected, it must be in contact or near to the oscillating bubbles, 
which is achieved by the acoustic radiation force that pushes bubbles against the 
endothelium (81). At high acoustic pressures, the bubbles undergo “inertial” cavitation, 
expanding and collapsing rapidly causing them to burst, which can create high local 
temperatures and pressures, velocity jets, and the generation of free radicals (80).  
At higher power and duty cycles (the fraction of time ultrasound is turned on), FUSwMB 
can also lead to thermal effects. At temperatures greater than approximately 60ºC, FUS 
can be used as a thermal ablation method and has been used to treat tumors in many 
organs including the liver, breast, kidney, bone, uterus and pancreas (70,82–85). It has 
also been used as a technique of inducing thermal coagulation in blood vessels (86–90). 
1.6 The effect of FUS parameters on BBB Disruption 
Much of the early work on BBB disruption mediated by FUSwMB has been focused on 
optimizing the pulsed FUS exposure parameters in order to produce consistent, localized, 
and persistent BBB disruption, with minimal damage to the brain. There are several key 
FUS and MB parameters that can influence the type and extent of the induced BBB 
disruption. These include the frequency of the ultrasound, the applied pressure amplitude 
or acoustic power, pulse sequence parameters such as burst length (BL), pulse repetition 
frequency (PRF), and duty cycle (DC), exposure time, and contrast agent parameters such 
as size, concentration, and dose of the MB (68–75). 
The pre-clinical RK-100 system developed by FUS Instruments Inc. was used for all 
experiments included in this thesis. The ultrasound was generated using a spherically 
focused piezoceramic transducer (f0=0.563 MHz), with a 7 cm diameter, and a focal 
length of 5.6 cm. The transducer was driven by a function generator generating sinusoidal 
excitations, which were amplified with a radiofrequency (RF) power amplifier.  
1.6.1 Transducer Frequency 
Since we are working with a non-invasive transcranial approach, identifying the right 
transducer frequency range is necessary for adequate depth penetration and energy 
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deposition in the focal zone. High transducer frequencies are not optimal for transcranial 
FUS applications because of the decreased size of the focal volume, distortion of the FUS 
beam, and possible over-heating due to high absorption by the bone (91). A study 
published by McDannold et al. in 2008 comparing the effect of five transducer 
frequencies, 0.26, 0.69, 1.5, 1.63, and 2.1 MHz, found BBB disruption was observed in 
frequencies as low as 0.260 MHz, without any ischemia, apoptosis, or any long-term 
damage from histology (92). Interestingly, a study published in 2010 by Liu et al. using a 
planar pinhole ultrasound transducer was able to achieve BBB disruption at a frequency 
as low as 26 kHz (93). Figure 1-6 demonstrates local BBB disruption using contrast 
enhanced T1-weighted magnetic resonance imaging (MRI) in a rabbit brain at four 
ultrasound frequencies (92). 
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Figure 1-6: Focal contrast enhancement from dynamic contrast enhanced magnetic 
resonance imaging (DCE-MRI) after focused ultrasound with MB administration 
(FUSwMB) induced blood-brain-barrier (BBB) disruption in a rat at four 
frequencies: A) 0.26 MHz, B) 0.69 MHz, C) 1.63 MHz, and D) 2.07 MHz. Adapted 
from Hynynen et al. 2006 (92). 
1.6.2 Applied Pressure Amplitude or Power 
The applied pressure amplitude, also described by the acoustic power, controls the effect 
on the MB, and has effect on the BBB within the focal zone. A study in 2008 by 
A B 
C D 
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McDannold et al. investigated the induced BBB disruption for a range of applied powers 
(0.1-1.6 W), while all other parameters were held constant, and found that increasing the 
power increases the likelihood of causing BBB disruption. A summary of this result is 
shown in Table 1-1 (71).  
Table 1-1: The effect of a range of applied acoustic powers on blood-brain-barrier 
(BBB) disruption, while other parameters were held constant. All sonications had a 
duration of 20 s, and were performed using 50 ul/kg Optison microbubbles. 
Acoustic 
Power (W) 
Ultrasound 
Frequency 
(MHz) 
Burst 
Length 
(ms) 
PRF (Hz) Percentage with 
BBBD 
Mean signal 
enhancement in 
MRI 
0.1 0.69 0.1 1 20% (1/5) 0.8 ± 2.0% 
0.2 0.69 0.1 1 17% (1/6) 3.2 ± 4.2% 
0.3 0.69 0.1 1 60% (3/5) 7.2 ± 4.9% 
0.4 0.69 0.1 1 100% (4/4) 12.6 ± 2.3% 
0.5 0.69 0.1 1 100% (4/4) 13.1 ± 3.1% 
 
1.6.3 FUS Pulse Sequence 
Another important factor in FUS is the pulse sequence used, which is defined by three 
main parameters: 1) burst length (BL), which is the duration for which ultrasound is on in 
each pulse, 2) pulse repetition frequency (PRF), which is the number of pulses applied 
per second, and 3) duty cycle, which is the percentage of the total duration for which the 
ultrasound is on. An example of a commonly used pulse sequence for FUSwMB induced 
BBB disruption is shown in Figure 1-7.  
16 
	  
Figure 1-7: A commonly used pulse sequence for focused ultrasound with 
microbubble administration (FUSwMB) induced blood-brain-barrier (BBB) 
disruption with a burst length (BL) of 10 ms, a pulse repetition frequency (PRF) of 1 
Hz, for a 1% duty cycle. 
Several studies have aimed to characterize the effects of various pulse sequences on BBB 
disruption. A study by McDannold et al. in 2008 concluded that reducing the BL from 10 
ms to 0.1 ms significantly reduced the MRI contrast enhancement, a surrogate of BBB 
disruption, where as altering the PRF alone had no effect on BBB disruption, at least over 
a particular range from 0.5 to 5 Hz (71). In 2011, Choi et al. published a study which 
demonstrated the trans-BBB delivery of 3-kDa dextran at BLs as short as 0.03 ms, with 
increased delivery of dextran as the BLs were increased up to 30 ms (94). However, more 
heterogeneous distribution of dextran was also observed at higher BLs. Also in 2011, 
O’Reilly et al. published a similar study using a new accurately timed short burst of 3 µs, 
with burst delays ranging from 6 to 600 µs within the BL of each pulse (95). These short 
bursts and delays were introduced to increase the number of bursts within the previously 
reported 10 ms BL. A semi-log relationship was found between MRI contrast 
Burst	  Length	  =	  10	  ms 
Pulse	  Repetition	  Frequency	  =	  1	  Hz 1	  s 
Duty	  Cycle	  =	  	  1% 
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enhancement and the number of bursts in a pulse, with a single 3 µs burst still capable of 
inducing BBB disruption. Although no improvements in safety over longer bursts were 
established, closely-timed micro-pulses, as low as 3 µs BL, or even a single shot 3 µs 
pulse, may allow for a greater level of treatment control (95). 
1.6.4 Exposure Time 
In 2010, Chopra et al. published a study examining the influence of exposure time on 
BBB disruption in rats in order to help determine the optimal treatment delivery 
conditions. Using a 1.08 MHz transducer, and at an applied pressure amplitude of 0.38 
MPa, it was determined that exposures less than 180 s in duration are associated with a 
low probability of irreversible damage to brain tissue. Although exposures greater than 
300 s were associated with an increased proportion of irreversible brain damage, this may 
be acceptable for chemotherapy delivery, in which tissue destruction is one of the 
therapeutic goals. It was also found that weekly repeat exposures were feasible, but 
resulted in evidence of tissue damage over the focal volume in 50% of the animals (72).  
1.7 The effect of MB on FUS  
The use of MB allows for nucleation of cavitation sites to disrupt the BBB. This allows 
us to significantly reduce the applied acoustic energy resulting in far greater consistency 
in BBB disruption, since high intensity ultrasound required to generate cavitation bubbles 
in the blood are no longer needed (96). Use of MB also improves the practicality and 
safety of the procedure by reducing the risks of overheating and tissue damage that can 
result from intertial cavitation (97).  
Three commonly used commercially available gas-filled MB are Definity (Lantheus 
Medical Imaging, USA), Optison (GE Healthcare, USA), and SonoVue (Bracco 
International, The Netherlands). A comparison of the physical characteristics of these 
common MB are presented in Table 1-2. 
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Table 1-2: Comparison of three types of microbubbles (MB) that are commonly 
used for blood-brain-barrier (BBB) disruption; Definity, Optison, and SonoVue. 
MB Type Shell material Gas Mean size 
(um) 
Concentration 
(bubbles/mL) 
MB half-life 
(mins) 
Optison Albumin C3F8 2.0-4.5 5.0-8.0x108 2.5-4.5 
Definity Phospholipid C3F8 1.1-3.3 1.2x1010 2-10 
SonoVue Phospholipid SF6 2-8 0.9-6x1010 3-6 
Several studies have investigated the physical effect MB have on BBB disruption, but 
only one attempted to characterize the effect of different MB’s using the same acoustic 
parameters. In 2007, McDannold published a study showing that Optison produced a 
larger effect then Definity for a sonication at 0.5 MPa (71). Since Definity MB’s are 
more concentrated than Optison, the author speculated that this could result from the fact 
that the lipid shell of Definity being more difficult to oscillate, and thus cavitate, or that 
the larger bubble size of Optison MB is closer to the resonant size at the transducer 
frequency, causing a greater cavitation effect. Other studies investigating the effect of 
MB properties also found that the extent of cavitation, and the induced disruption is 
bubble-size dependent (79).  
However, more investigation is required to understand the effect of each physical MB 
property has on the mechanism and ultimately extent of BBB disruption. Yang et al. used 
three doses of SonoVue 150, 300 and 450 µl/kg in a rat brain model, and found increased 
Evans blue (EB) extravasation with increasing MB doses. They also detected 
intracerebral hemorrhage with T2-weighted MRI at the higher MB doses, but not at 150 
µl/kg. Treat et al. concluded that although increasing the dose of Optison (10 to 50 µl/kg) 
led to a greater concentration of the chemotherapeutic agent doxorubicin being delivered 
to the brain, it was also accompanied by more profound indications of tissue damage 
(98). In another study, McDannold et al. observed that MB dose had no effect on BBB 
disruption over the range of 50 to 250 µl/kg of Optison (71), while Choi et al. reported 
that fluorescence intensity of tagged dextran was not significantly different among 10, 50 
and 250 µl/kg of Definity at 0.46 MPa (99). 
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1.8 Pre-clinical drug delivery studies using FUS sonication 
with MB administration 
1.8.1 Delivery across the Disrupted BBB 
BBB disruption induced by FUSwMB has been used in pre-clinical studies to enhance 
the delivery of a range of molecules across the BBB, including imaging contrast agents 
(71,72,74,92), neurotherapeutics (100–102), antibodies (73), nanoparticles (103), 
fluorescence agents and dyes (94,99), and chemotherapeutic agents in tumor models 
(100,104–109). A summary of the agents delivered is provided in Table 1-3.  
Table 1-3: Pre-clinical studies on delivery of different molecules and cells across 
disrupted blood-brain-barrier (BBB) following focused ultrasound with 
microbubble administration (FUSwMB). 
Type Agent Size 
MRI or SPECT contrast agent Omniscan (72–74) 573 Da 
Magnevist (92) 938 Da 
99mTc-DTPA (101) 492 Da 
Superparamagnetic iron oxide (111) 50 nm 
Dyes and fluorescence agents Evans Blue (68,106)  ~ 70 kDa 
Dextran (94,99)  3 kDa - 70 kDa 
Therapeutic compounds Doxorubicin (98,100–102)  544 Da 
BDNF (112)  27 kDa 
Antibody Herceptin (113) 148 kDa 
D4 rabbit receptor-targeting (73) 42 kDa 
Nano particle Magnetic nanoparticles (114) 74-83 nm 
Gold nanoparticles (103) 50 nm 
Due to the range of sizes and types of molecules that can be delivered across a disrupted 
BBB, created by FUSwMB, it highlights the importance to develop in-vivo imaging tools 
that can be used to monitor and quantify the increased endothelial permeability, which 
can act as a quantitative surrogate of the delivery of the intended molecule. 
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1.8.2 Delivery across the BTB in Glioma Models 
Drug delivery in tumors is more complex than the normal brain, which has an intact 
BBB. Over time, the permeable BTB leads to the development of vasogenic edema, 
which results from plasma plus plasma proteins leaking into the brain parenchyma (67). 
This edema, combined with the lack of a lymphatic drainage system in the solid tumor 
mass, elevates the interstitial fluid pressure in and around the tumor –creating a barrier 
for drug delivery, particularly for larger molecules that are unable to diffuse across the 
BTB, and must resort to convective fluid transport (66,115). A summary of pre-clinical 
glioma studies investigating delivery of imaging or therapeutic agents across the BTB, 
following FUSwMB are listed in Table 1-4. 
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Table 1-4: Summary of studies on delivery of imaging or therapeutic agents across 
the blood-tumor-barrier (BTB) following focused ultrasound with microbubble 
administration (FUSwMB) (100,104–109,116,117). 
Author Agent, Tumor Results 
Treat et al, 
2012 (109)  
Liposomal 
Doxorubicin 
 (80-90nm), 
Rat 9L 
- FUSwMB + Liposomal Doxorubicin (DOX) reduced tumor growth 
compared to DOX only 
- Significant increase in median survival after single treatment 
Aryal et al, 
2013 (100)  
Liposomal 
Doxorubicin 
(80-90nm), 
Rat 9L 
- 3x weekly treatment sessions of FUSwMB + DOX provide 
complete tumor suppression and improve survival nearly 100% 
Aryal et al, 
2015 (108)  
Liposomal 
Doxorubicin 
(80-90nm),  
Rat 9L 
- DOX concentrations significantly enhanced compared to control 
tumor following FUSwMB at days 9,14, and 17 
- Volume transfer constant (Ktrans) significantly enhanced compared 
to control tumor at day 9, but not 14 or 17 
- No correlation between DOX delivery and Ktrans, possibly due to 
size mismatch of liposomal DOX (~100 nm) and Gadolinium (Gd)-
DTPA (938 Da) 
Wei et al, 2013 
(104) 
Temozolomide 
(194 Da), 
Rat 9L 
- Temozolomide (TMZ) Cerebrospinal fluid (CSF)/plasma ratio up 
from 23% to 39% in FUS + TMZ group 
- FUS + TMZ group 7–day tumor progression ratio reduced from 24 
to 5, and extended median survival from 20 to 23 days 
Liu et al, 2014 
(105)  
Temozolomide 
(194 Da), 
Mice U87 
- Local TMZ accumulation increased from 6.98 to 19 ng/g following 
FUSwMB 
- Decreased tumor volume and improved animal survival found with 
increased TMZ doses (up to 15 and 30%, respectively) 
Liu et al, 2010 
(106)  
BCNU 
(214 Da) 
Rat C6 
- FUSwMB increased delivery by 202%, 
- FUSwMB prior to BCNU decreased tumor volume (0.05 vs. 0.28 
cm3 at day 31) and animal survival relative to untreated controls 
(85.9%), compared to BCNU alone 
- BCNU alone did not decrease tumor volume, but did significantly 
improve survival (15.7%) 
Park et al, 
2012 (107)  
Trastuzumab 
(145 kDa) 
Rat HER2 
- From week seven of treatment to end of study, mean tumor volume 
of FUSwMB + trastuzumab decreased compared to control groups 
- In combined group, 4/10 tumors completely resolved on MRI, and 
median survival 32% longer than untreated control group 
Chu et al, 2013 
(118)  
Gd-DTPA 
(938 Da) 
Rat C6 
- FUSwMB significantly increased permeability of small tumors, 
measured with R1 relaxometry and area under the curve (AUC) 
-Accumulation was higher in large tumors, independent of FUSwMB 
Yang et al, 
2014 (117) 
Gd-DTPA 
(938 Da) 
Rat F98 
- Ktrans of sonicated tumor was 2.46x higher at 20 min, and 1.78x 
higher at 24 h post, compared to untreated tumor 
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1.9 Computed Tomography (CT) Perfusion  
1.9.1 Imaging the Delivery of Blood Borne Solutes across the BBB 
Imaging contrast agents, such as gadolinium based Omniscan and Magnevist has been 
commonly used to investigate and characterize BBB disruption (71,72,74,92). 
Furthermore, tracer kinetic analysis of dynamic contrast enhanced (DCE) studies can 
provide more quantitative and functionally relevant information about the 
cerebrovascular system, in particular, Ktrans, which is the volume transfer rate of solutes 
from blood to extravascular extracellular space in the brain parenchyma (interstitium) and 
is related to the permeability surface area product (PS) of endothelial permeability (P) 
and surface area (S) of the perfused blood vessels. This transport parameter more 
accurately measures BBB disruption and predicts drug delivery in a target volume, 
necessary for clinical translation of FUS for increased drug delivery to the brain.  
Studies in mice using DCE MRI demonstrated that Ktrans in the sonicated hemisphere of 
the brain was found to be least an order of magnitude higher than that in the contralateral 
hemisphere, within a range of ultrasound exposure parameters that induced minimal or no 
vascular damage (101,119,120). The study by Park et al also demonstrated that Ktrans at 
30 minutes post FUS showed a linear correlation with doxorubicin delivery to the 
sonicated regions (101). 
For quantitative DCE techniques, CT has advantages over MRI mainly because of the 
higher temporal resolution while maintaining sub millimeter resolution and superior 
quantitative accuracy (121). DCE-CT methods have been used to quantify PS in tumor 
models (122), high-grade glioma (123), and in stroke patients (124).   
CT Perfusion, similar to DCE-MRI, is based on imaging methods that characterize tissue 
hemodynamics by modeling the transport of contrast through the vascular bed into the 
tissue through a permeable endothelium, e.g. a disrupted BBB from FUSwMB. In DCE-
MRI, the contrast from gadolinium-based agents is generated via interactions with nearby 
water molecules, whereas in CT Perfusion, the contrast from iodinated agents comes 
from the attenuation of x-rays, measured in Hounsfield units. The typical CT Perfusion 
protocol involves two serial phases: 1) continuous acquisition phase where images are 
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acquired rapidly (~1s per image), and should last long enough to capture the initial wash-
in and wash-out of the bolus (~30-40s), and 2) delay phase where images are acquired 
less frequently (every 10-15s) to observe the slow exchange of contrast between the 
blood and tissue through the permeable endothelium. The quantitative evaluation of 
transport parameters from a CT Perfusion study is based on the theoretical concept of the 
impulse residue function R(t), which describes the concentration-time curve in the ROI, 
Ce(t), when any unit amount of contrast is instantaneously introduced into the arterial 
input of a tissue region. 
Empirically, R(t) is the fraction of contrast that remains within the tissue as a function of 
time following an instantaneous contrast injection in the arterial input. Given that the 
measured signal intensity varies linearly with contrast concentration, and assuming that 
the blood flow (F) and PS are constant within the period of measurement, the tissue time-
concentration curve Ce(t) can be obtained from the convolution between the arterial input 
function, Ca(t), and the model dependent impulse residue function, R(t) (125). This 
relationship can be mathematically expressed as: 
 
                       … Equation 1-3 
where  is a convolution operator. 
1.9.2 General Closed Two-Compartmental Model 
The general closed two-compartmental model, which defines the intravascular space and 
the extravascular interstitial space as well-mixed compartments, is commonly used to 
evaluate Ktrans (126). Unlike open compartmental models, in which the contrast is 
‘explicitly’ allowed to be cleared from the system, closed compartmental models do not 
consider any vascular or extravascular clearance. Since contrast agents are usually inert 
(i.e. not metabolized) in tissue, tracer kinetic modeling of the contrast agent distribution 
can be achieved with only two compartments. By using a compartment to model 
intravascular space (vessels), it is implicitly assumed that the transit time through the 
)()()( tRtCFtC ae ⊗⋅=
⊗
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vessels is ignored. A schematic of the closed two-compartment model is shown in Figure 
1-8.  
 
Figure 1-8: A schematic of the general closed two-compartment model that 
distributes contrast between the intravascular space and the interstitial space, as 
two separate ‘well-mixed’ compartments. Adapted from Lee et al. 2003 (127). 
To model the distribution in the interstitial space, the following equation can be written 
by applying the Fick Principle (conservation of mass): 
               … Equation 1-4 
   
where Cb(t), Ca(t), and Ce(t), are the blood, arterial, and interstitial concentration of 
contrast agent solute, respectively; Ve is the distribution volume of contrast agent in the 
interstitial space; K1 or Ktrans is the forward volume transfer constant from the 
intravascular space into the interstitial space and is equal to the backward volume transfer 
constant because of the assumption that passive diffusion is the exchange mechanism 
between the two spaces (see Section 1.9.3). The solution for Equation 1-4 leads to an 
expression for the interstitial concentration of contrast agent: 
)()()( tCKtCK
dt
tdCV etransbtransee −⋅=
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               … Equation 1-5 
and  is the backflux rate constant from interstitial space to intravascular space 
Since a CT scanner measures tissue enhancement that has contribution from both the 
intravascular and interstitial space, thus: 
 
 
   … Equation 1-6 
where Q(t) is the mass of contrast agent in a unit mass of tissue.  
Equation 1-6 becomes the operating equation for the estimation of the functional 
parameters: Ktrans, Ve and Vb, which can be achieved using a variety of nonlinear 
regression methods (128). Equation 1-6 can be simplified by invoking the assumption 
that there is no backflux of contrast agent from the interstitial to intravascular space 
(129): 
                           … Equation 1-7 
Equation 1-7 is better known as the Patlak plot (130):  if   is plotted vs , 
the result is a straight line with a slope of Ktrans and an intercept of Vb.  Although useful 
for quantifying the rate of delivery across the BBB as Ktrans, it is doubtful whether the no 
backflux assumption is valid in tumor imaging. In the next section, we show that Ktrans is 
equal to the blood flow (F) and extraction efficiency (E) product: FE. The mass of solute 
delivered to the tissue and can diffuse into the interstitial space is 𝐹 ∙ 𝐶! 𝑡 − 𝐶!(𝑡) . 𝐸 
is defined as : 
                            … Equation 1-8 
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or the fraction of this mass that is actually transferred from the vascular to interstitial 
space, during a single passage of blood from the arterial end to the venous end of the 
capillaries of a tissue (131).   
A drawback of compartmental models is that F and E (PS) cannot be measured separately 
because they are determined together as Ktrans. This is expected because by assuming the 
intravascular space as a well-mixed compartment all information related to the 
convective transport of solute along the capillaries is lost.  
1.9.3 Johnson and Wilson Model 
As opposed to compartment model with spatially uniform contrast concentration, the 
intravascular space of the Johnson and Wilson model has a concentration gradient from 
the arterial to the venous end of capillaries from the diffusion of contrast across the 
capillary endothelium into the interstitial space as blood travels down the length of 
capillaries. The Johnson and Wilson (JW) model (132) is one that models both the 
convective transport of contrast in blood vessels and the diffusion of contrast between 
vessels and interstitial space. In brief, the model lumps all the capillaries together into a 
single cylinder of length L and volume Vb, with a permeability surface area product PS, 
while the interstitial space is assumed to be a cylindrical annulus around the capillary, 
which behaves like a well-mixed compartment. As a result, it allows for the separate 
estimation of F and E (PS), which is not possible with a compartmental model. 
In this section, the JW model is used to justify the expression, Equation 1-8, for the 
extraction efficiency (E).  The impulse residue function, R(t) of the model, which forms 
the basis of kinetic analysis of the subsequent chapters, will be introduced in the next 
section. 
As the blood borne contrast enters the capillary, it starts to diffuse across the capillary 
endothelium into the interstitial space, thus the blood concentration of contrast, Cb will be 
a function of both axial position, x, along the capillary as well as time, t.  The interstitial 
concentration of solute is Ce(t) and depends only on time, because the interstitial space is 
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treated as an ‘evenly-mixed’ compartment. A schematic of the Johnson and Wilson 
distributed parameter model is shown in Figure 1-9. 
 
Figure 1-9: A schematic of the Johnson and Wilson distributed parameter model. 
Adapted from Lee et al. 2003 (127). 
The transport and exchange of solute through the capillaries can be described by the 
following equation: 
          … Equation 1-9 
For the case when Ce(t) is a constant,  say Ce, Equation 1-9 has the solution: 
         … Equation 1-10 
where H(t) is the unit step function.  As expected, at x = 0 Cb(x,t) = Ca(t) and  
         … Equation 1-11 
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Further the arterio-venous difference can be written as: 
               … Equation 1-12 
where is the capillary transit time. Thus,  
             … Equation 1-13 
as Crone (131) and Renkin (133) have previously derived. Moreover, the Fick Law gives 
the change in the interstitial concentration as:             
                                                              …Equation 1-14 
which, according to Equation 1-13 can also be expressed as  
                   … Equation 1-15 
Equation 1-15 can be interpreted as that the forward flux rate from the capillary to the 
interstitial space is and the back-flux rate from the interstitial space to the 
capillary is FE⋅Ce. Thus, FE is the unidirectional flux rate of solute per unit 
concentration, or volume transfer constant, from blood to interstitial space or from 
interstitial space to blood. The above derivation is obtained under the special case when 
Ce(t) is held constant in time.  For the general case when Ce(t) is an arbitrary function of 
time, St. Lawrence and Lee has shown that the unidirectional flux of solute per unit 
concentration is still FE (134).   
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1.9.4 Adiabatic approximation leading to the Johnson-Wilson-Lee 
Model 
Distributed parameter model has an advantage over closed two-compartmental model in 
kinetic analysis of DCE MRI or CT studies because it allows blood flow (F) and 
permeability surface product (PS) or extraction efficiency (E) to be estimated separately 
which is not possible with compartmental models. Distributed parameter models allow 
for the separation by introducing a concentration gradient from the arterial to the venous 
end of the capillary (127). This gradient models the leakage of contrast through 
permeable endothelium into the tissue as blood traverses the length of the vessels.  
The governing equations of the Johnson and Wilson model can be written as: 
 
                                 … Equation 1-9 
  … Equation 1-16 
Equation 1-9 describes the convective and diffusional transport of solute in capillaries, 
while Equation 1-16 gives the rate of change of solute concentration in the interstitial 
compartment. The solution (impulse residue function) of the Johnson and Wilson model 
can only be expressed in the frequency domain with use of Laplace transform (132), 
which had severely limited its application in the kinetic analysis of DCE MRI or CT 
studies. This was until St Lawrence and Lee discovered an adiabatic approximation to 
derive an analytical solution of the model in the time domain (134).  
There are two main motivations for using the adiabatic approximation. First, it can be 
assumed that the time rate of change of Ce(t) is much slower than that of Cb(x,t), such that 
Ce(t) can be approximated by a staircase function consisting of discrete, finite steps 
provided the time interval of each step is small relative to the transit time of the 
capillaries. With this approximation Ce(t) is constant within each step of the staircase. 
Second, as discussed above in the solution of Equation 1-9, when Ce(t) is a constant, 
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Cb(x,t) can be expressed in terms of Ce(t).  Thus, at each step of the staircase 
approximation of Ce(t),  Equation 1-9 is solved for Cb(x,t) in terms of Ce(t). With Cb(x,t) 
expressed in Ce(t), Equation 1-16 can be used to determine the increase in Ce(t) at the end 
of the step.  This procedure can be repeated for each step in the staircase approximation 
of Ce(t) resulting in a time domain solution for the mass of solute per unit mass of tissue, 
Q(t), which can be expressed as:  
 
  … Equation 1-17 
where  is a convolution operator and R(t) is expressed as: 
  … Equation 1-18 
 
 
 
 
 
 
 
Figure 1-10: The blood flow scaled impulse residue function according to the 
Johnson and Wilson model.  The symbols are defined in the text. Adapted from Lee 
et al 2003 (127) . 
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Figure 1-10 is a plot of F⋅R(t) or the blood flow scaled impulse residue function.  It lends 
itself to the following interpretation: if a bolus of contrast agent is injected directly into 
the arterial inlet of the tissue, so that Ca(t) is non-zero for a very short while and the area 
under Ca(t) is unity, the total mass of solute delivered to the tissue is numerically equal to 
F. The blood flow scaled impulse residue function, F⋅R(t), therefore would reach a height 
of F immediately and maintains this height for a duration equal to the mean transit time 
(MTT) of the tissue, Vb/F.  The area under the curve for when the bolus is traversing the 
length of the capillary is the blood volume, Vb, and is represented as the shaded area in 
Figure 1-10.  After a time equal to Vb /F, unextracted contrast agent starts to leave the 
tissue, F⋅R(t) drops to a height of FE and thereafter contrast agent in the interstitial space 
back diffuses into the intravascular space and is washed out by blood flow.  This portion 
of F⋅R(t) is described by a decreasing monoexponential function with a rate constant 
equal to FE/Ve. With Ca(t) and Q(t) measured by CT scanning, F⋅R(t) can be determined 
by model deconvolution (135) according to Equation 1-18 to yield the parameters: F, Vb, 
MTT and E (PS). 
1.9.5 In-vivo Diffusion and Flow Limited Solute Exchange  
In the context of drug delivery, the volume transfer constant Ktrans (FE), which is 
estimated by the JW model, is more important for drug delivery than PS alone. When 
predicting PS, there exists three regimes for the diffusive exchange of solute between 
blood and interstitial space: 1) when PS << F, FE approximates PS, the exchange is 
diffusion-limited; 2) when PS is of the same magnitude as F, the exchange is neither 
diffusion nor flow limited; and 3) when PS >> F, so that FE approaches F, the exchange 
is flow-limited. 
In the diffusion-limited scenario, as is with disrupted BBB, we can approximate FE with 
PS, meaning the slope of the Patlak analysis in Equation 1-7 can be used to estimate PS. 
In brain tumors, where the BTB PS is significantly elevated (136), PS << F  is no longer 
true, therefore FE is not the same as PS, and FE is the correct functional parameter to 
predict drug delivery.  
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PS measures the diffusional flux between two semi permeable compartments at different 
concentration of the contrast agent (blood borne solutes) where the content of the 
compartments is not moving. In the in-vivo situation, whereas interstitial fluid is not 
moving, blood in the capillaries is moving from arterioles to venules while blood borne 
solutes are exchanging by diffusion with the interstitial fluid. When endothelial 
permeability is increased, whether it’s from the gaps between tight junction proteins that 
are opened up following FUSwMB (75), or in brain tumors, where progression is 
accompanied by breakdown in the BTB (136), the transfer of solutes across the 
endothelium is no longer governed by diffusion alone, but also by pressure driven fluid 
flow across such gaps, as governed by Starling’s Law:  
 
   𝐽𝑐 = 𝐿𝑡𝑆𝑣(1 − 𝜎𝑠)(∆𝑝! − 𝜎∆Π)  … Equation 1-19 
where Jc is the convective flux of solute across the disrupted BBB or BTB, Lt is the 
hydraulic conductivity, Sv is the vascular surface area, Δp is the transmural hydrostatic 
pressure gradient, ΔΠ is the transmural osmotic pressure gradient pressure gradient, σ is 
the osmotic reflection coefficient, and σs is the solute’s reflection coefficient. 
Starling’s law, which forms the basis of Equation 1-19, states that the fluid flow across 
the wall of a capillary is dependent on the balance between the hydrostatic pressure 
gradient and the oncotic pressure gradient across the capillary. In the microvasculature, 
diffusion-driven solute fluxes are short lived and will proceed until the concentration of 
proteins are sufficient to oppose osmotic force of solute diffusion (until σ∆Π = 0), and 
occurs independent of changes in the net filtration pressure. By plotting the cumulative 
solute flux, Jt/S, against the change in interstitial oncotic pressure (σ∆Π), the Peclet 
number, which is the ratio of the contributions to solute transport by convection to those 
by diffusion, can be calculated to identify the extent of solvent drag present (i.e. the 
contribution from convective solute flux) (137,138). When there is sufficient solvent 
drag, solute transfer from capillary to interstitial fluid is neither diffusion nor flow limited 
and may no longer be dependent only on PS.  However, by interpreting Ktrans (FE) as 
having contribution from both convective and diffusive flux across the endothelial 
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barrier, as opposed to diffusion alone, the Johnson-Wilson-Lee (JWL) model could be 
extended to include both solute transfer processes. 
1.10 Research Goals and Objectives 
The work presented in this thesis focused on two major goals: 1) Using CT Perfusion to 
measure the PS following FUSwMB, in rats with an intact BBB, and 2) Evaluating the 
BTB PS response following FUSwMB in a C6 rat glioma model. These goals were 
accomplished by achieving the following objectives: 
1. Titrate FUS exposure parameters to induce a quantifiable and transient BBB 
disruption as demonstrated by an increase in PS, with minimal tissue damage. 
2. Evaluate the acute BTB response following FUSwMB at the exposure parameters 
found in objective 1. 
3. Evaluate the 24-h, and 72-h BTB PS response following FUSwMB using small 
and large CT contrast agents. 
4. Measure edema volume with MRI and CT Perfusion derived vascular distribution 
volume, Ve, following FUSwMB. 
5. Perform histological and immunohistological analysis to identify the anatomical 
correlates involved in BTB response following FUSwMB.  
1.11 Thesis Outline 
1.11.1 FUS sonication with MB administration Induced BBB 
Disruption: Quantifying the Increased Endothelial Permeability 
using CT Perfusion (Chapter 2) 
For clinical translation of FUSwMB, as a novel technique to improve drug delivery 
across the BBB, it is important to evaluate the safety and efficacy of a range of possible 
parameters, and demonstrate that CT Perfusion can quantify the increase in BBB PS to 
monitor and predict drug delivery. The purpose of this study was to evaluate CT 
Perfusion as a tool for quantifying BBB PS following disruption following FUSwMB.   
1.11.2 Using small (750 Da), and large (65 kDa) contrast agent in CT 
Perfusion to quantify BTB PS response following FUS 
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sonication with MB administration in a C6 rat glioma model 
(Chapter 3) 
Small molecules such as temozolamide, and large molecules such as bevacizumab, are 
routinely used, often in combination, to treat glioma. Small and large molecules have 
different contributions of diffusive and convective transport across the BTB, as the 
governing mechanism of transport. To understand the BTB PS response for small and 
large drugs, we used CT contrast agents of different sizes, Isovue (760 Da) and eXia (65 
kDa) to evaluate BTB PS following FUSwMB.  
1.11.3 Investigating the decrease in edema following FUS sonication 
with MB administration using MRI and vascular distribution 
volume, measured from DCE-CT (Chapter 4). 
A decrease in BTB PS following FUSwMB, measured with a diffusible small molecule 
contrast, should decrease the associated vasogenic edema, resulting in a decrease in the 
abnormally elevated IFP. This decrease in IFP should also partially restore the 
transvascular pressure required for the convective transfer of large molecules across the 
BTB.  The purpose of this study was to investigate the change in vasogenic edema 
following FUSwMB, using qualitative and quantitative MRI, and CT Perfusion derived 
contrast distribution volume, as well as to investigate the mechanisms behind the 
resulting BTB response with histopathology.   
1.11.4 Conclusion and Future Work (Chapter 5) 
In the final chapter, the major findings of this thesis are summarized, and their 
experimental and clinical relevance are discussed. The potential of FUSwMB for 
increased drug delivery in brain tumors is proposed, and some future experimental 
directions are presented.  
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Chapter 2  
2 Focused Ultrasound Sonication with Microbubble 
Administration Induced Blood-Brain-Barrier Disruption: 
Quantifying the Increased Endothelial Permeability 
Surface Area using Dynamic Contrast Enhanced-
Computed Tomography in Rabbits 
2.1 Introduction 
The blood-brain-barrier (BBB) consists of endothelial tight junctional complexes 
surrounded by associated anatomical and functional structures, with a combined purpose 
to limit solute exchange between the blood and the central nervous system which requires 
a tightly controlled homeostasis for its proper functioning (1). The undesired 
consequence is that it is the single most limiting factor in the delivery, and thus 
development of neurotherapeutics (2). Typically, only lipid soluble drugs with molecular 
masses less than approximately 500-Da are able to passively diffuse through the lipid 
bilayer (3). 
Over the years, a number of trans-BBB delivery strategies had been experimented with 
and clinically implemented, but there are limitations related to the invasive nature of 
these techniques (4) or the non-localized disruption caused by systematically delivered 
agents that temporarily increase BBB permeability (5). The modification or conjugation 
of drugs with liposomes (6), nanoparticles (7) or peptide vectors (8) to increase 
permeability across the BBB has been shown to be promising, but these methods also 
suffer from toxicity and non-selectivity issues, and would benefit by being supplemented 
with other approaches. 
Recent advances in acoustic technology have opened the door for an exciting new 
strategy to reversibly disrupt the BBB with the use of focused ultrasound (FUS). FUS 
allows for the concentration of acoustical energy within a focal spot, with minimal effects 
to near-field tissue, and can thus be used to non-invasively induce biological effects in 
the body (9). In the brain, when FUS is pulsed in the presence of intravenously injected 
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gas filled microbubbles (MB), interactions between the sonicated bubbles and the 
endothelium induce BBB disruption (10). It has been proposed that the mechanical 
effects involved in this process may be associated with the mechanical stresses induced to 
the vessel walls (11) and/or radiation force induced bubble movement (12). 
Electron microscopy studies have demonstrated that the disruption was a result of the 
breakdown and widening of the tight functional complexes that maintain BBB integrity, 
and was restored within 4 hours at appropriate sonication parameters (13), with no or 
minimal vascular damage (14,15). Studies have demonstrated that the dynamics of the 
opening were dependent on different acoustic parameters such as frequency, applied 
pressure amplitude of the ultrasound, sonication time, burst length, and pulse repetition 
frequency of the ultrasound, and on the size and dose of MB’s (16–18). 
FUS sonication with MB administration (FUSwMB) BBB disruption has previously been 
used in pre-clinical studies to enhance the delivery of a range of molecules across the 
BBB, including chemotherapeutic agents (19), fluorophores (20), nanoparticles (21), and 
antibodies (22). However, to translate this technique into clinic, or for therapeutic 
evaluation in clinical trials, it is necessary to investigate markers that can be used to 
monitor and measure the increased permeability of the BBB. These markers can also be 
used as surrogates for predicting drug delivery over the targeted region, which are needed 
for increased confidence in the results of drug efficacy studies.  
Imaging contrast agent techniques, such as gadolinium (Gd)-enhanced magnetic 
resonance imaging (MRI), are commonly used to qualitatively investigate and 
characterize BBB disruption (14,16). However, tracer kinetic analysis of dynamic 
contrast enhanced imaging studies can be used to provide more quantitative and 
functionally relevant information such as cerebral blood flow (CBF), cerebral blood 
volume (CBV) and for our interests, the permeability surface area product (PS) of 
endothelial permeability (P) and surface area (S) of the perfused blood vessels (23). As 
discussed in Chapter 1 (Section 1.9.5), when PS is much smaller than the volume transfer 
constant (FE or Ktrans), it approximates the latter which represents the rate of solute 
extravasation per unit surface area from the perfused blood vessels into brain 
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parenchyma.  Therefore, PS can acts as a surrogate measure to model and predict drug 
delivery across a target volume of the BBB.  
In tracer kinetic modeling, most techniques estimate the volume transfer constant (FE or 
Ktrans) instead of estimating F and E separately to permit a calculation of PS according to 
Equation 1-13 (Chapter 1). Studies in mice using dynamic contrast enhanced (DCE) MRI 
have demonstrated that Ktrans in the sonicated hemisphere of the brain was found to be at 
least an order of magnitude higher than that in the contralateral hemisphere, within a 
range of FUS parameters that induce minimal or no vascular damage (24,25). The study 
by Park et al also demonstrated that the Ktrans at 30 minutes post FUSwMB showed a 
linear correlation with doxorubicin delivery over the sonicated region (24). 
For quantitative DCE techniques, CT could have advantages over MRI – mainly because 
of its greater spatial resolution and better quantitative accuracy in measuring tissue and 
blood contrast concentration (26). DCE-CT (or CT Perfusion) methods have been used to 
quantify PS in brain tumor patients (27), and also in stroke patients (28). In this study, we 
present our initial findings evaluating CT Perfusion as a tool for quantifying the increased 
endothelial PS following FUSwMB induced BBB disruption in a rabbit model. 
2.2 Methods and Materials 
2.2.1 Animals 
All experiments were approved by the Animal Use Subcommittee of the Canadian 
Council on Animal Care at our institution. Sixteen rabbits (2.2-4.0 kg) were anaesthetized 
with 2.5 % isofluorane using a nose cone, before their heads were shaved and depilated 
and a catheter was inserted into a saphenous vein. Ketamine-xylazine (10:1) was then 
administered at a rate of 5-10 ml/hr via the catheter as isofluorane was turned off. The 
first two rabbits underwent FUSwMB where BBB disruption was monitored by MRI 
followed by CT Perfusion imaging up to 40 minutes post. The remaining fourteen rabbits 
underwent baseline CT Perfusion imaging before FUSwMB, followed by serial CT 
Perfusion imaging out to 270 minutes.  
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Twenty minutes after anesthesia was switched from isofluorane to ketamine-xylazine, 
baseline CT Perfusion scans were performed, after which the rabbits were placed on the 
FUS system for FUSwMB.  Immediately following sonication, 7-10 ml of Evans Blue 
(EB) dye was intravenously injected via the saphenous vein catheter and allowed to 
circulate for the duration of the study for histological confirmation of BBB disruption 
after sacrifice. Follow-up CT Perfusion scans were performed at 5, 15, 30, 45, 60, 90, 
120, 150, 180, 210, 240, and 270 minutes post at which point the rabbit was sacrificed. 
 
Figure 2-1: Schematic of the setup of a focused ultrasound with microbubble 
administration (FUSwMB) experiment, showing  the rabbit head placed supine on 
the surface of the water tank of the FUS instrument, with the focal zone of the 
focused ultrasound transducer targeted in the brain. 
2.2.2 Focused Ultrasound Sonication with Microbubble 
Administration 
The rabbit was placed supine on the FUS system (RK100, FUS Instruments Inc., Canada) 
and was carefully positioned for optimal trans-cranially sonication, with the transducer 
aligned orthogonally to the surface of the rabbit’s head. A layer of ultrasound gel was 
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placed on the surface of the skull prior to sonication, to allow for smooth acoustic 
impedance transition from water in the FUS system to bone in the skull. A schematic of 
the experimental setup is provided in Figure 2-1. With the rabbit on the FUS system, an 
axial CT scan (140 kVp, 200mA, 1s rotation time, 2.5 mm slice thickness) was performed 
to locate a region in the right or left striatum. These coordinates were then input into the 
FUS system to target the located region. 
Each sonication was guided to the selected region and was pulsed with 10ms burst 
lengths at a 1 Hz pulse repetition frequency, for a 1% duty cycle (DC). The transducer 
was spherically focused with a diameter of 75mm, a radius of curvature of 60mm, and 
operated at a frequency of 0.763 MHz. Since this was a pilot study looking to identify a 
range at which we can measure the increase in BBB PS, we titrated the acoustic powers 
from 0.5-3.0 W and sonication times from 30-180s. We started at a power of 3 W before 
decreasing it to a range between 0.5-0.6 W, then began decreasing the sonication time 
down from 180s. The total applied sonication energy (Eapplied = Power x sonication time) 
was noted for each sonication.  
A single bolus of Definity (Lantheus Medical Imaging, USA) microbubbles at a dose of 
20 µl/kg and at a 1:10 dilution in saline, was manually injected via the saphenous vein 
catheter at the start of each sonication. All animals were sonicated once, except the last 
four rabbits which were sonicated four times, twice in each hemisphere at different 
locations. In the case of multiple sonications, 5 minutes were allowed to pass between 
MB injections. 
2.2.3 Magnetic Resonance Imaging 
In the first two rabbits, the sonications were guided by MRI (3T Verio, Siemens) using 
T2-weighted images (FSE, TE = 61.7 ms, TR = 2000 ms, ETL = 4, FOV = 6 x 6 cm, slice 
thickness = 1mm, 128 X 128). The BBB disruption was qualitatively confirmed using 0.2 
ml/kg Gd (Magnevist, Bayer Pharma) enhanced T1-weighted MRI (FSE, TE = 10 ms, TR 
= 500 ms) at 20 minutes post sonication before relocating to the CT scanner (VCT, GE 
Healthcare) where a CT perfusion study was performed at 40 min post. An area of 
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increased image intensity over the FUS targeted region in the Gd-enhanced T1-weighted 
images was used to qualitatively confirm BBB disruption. 
2.2.4 CT Perfusion Protocol 
The CT perfusion study used to quantitatively evaluate the BBB PS adopted a two-phase 
scanning protocol (First phase: two images per second acquired continuously for 30s with 
80 kV, 250 mA, 0.5s rotation time, 2.5 mm slice thickness; Second phase: one image 
acquired every 15s for another 180 seconds using the same scanning parameters as the 
first phase). A 5 ml/kg bolus of 300 mg Iodine/ml contrast (Isovue-300, 760 Da) was 
intravenously infused via the saphenous vein catheter over 5 seconds at the start of the 
first phase. 
2.2.5 Tracer Kinetic Analysis 
The Johnson-Wilson-Lee (JWL) distributed parameter model (23,29) was used to model 
the distribution of injected contrast in the brain (tumor) using permeability surface area 
product (PS), cerebral blood flow (CBF or F), cerebral blood volume (CBV or Vb), and 
the distribution volume of contrast in the brain parenchyma (Ve), as the model 
parameters. The technique is explained in detail in Chapter 1 (Section 1.9.4) of this 
thesis. One internal carotid artery was identified in the source CT perfusion images and a 
2 x 2 pixel region was placed in the artery to generate the time-density curve which was 
used as an arterial input function, Ca(t) to the JWL model. A typical arterial time density 
curve (input function) and the tissue time density curve, 𝑄(𝑡) from a rabbit study are 
shown in Figure 2-2.  
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Figure 2-2: Coronal head CT images of a representative rabbit, acquired with 
Isovue contrast injection, following focused ultrasound with microbubble 
administration (FUSwMB). The 2x2 voxel arterial input region of interest (ROI) 
and corresponding arterial time density curve, Ca(t), along with sonicated and 
control ROIs in the striata, and their corresponding time density curves Q(t) are 
presented. 
Under the assumptions that brain blood flow (F or CBF) is constant and Q(t) is linear 
with respect to the arterial concentration of contrast Ca(t), Q(t) is the product of F and the 
convolution of the arterial input function and the impulse residue function, R(t), of the 
JWL model, as shown in Equation 2-1. 𝑄 𝑡 = 𝐹 ∙ [𝐶! 𝑡 ∗ 𝑅 𝑡 − 𝑇! ]     … Equation 2-1 
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R(t) is defined as: 
   
𝑅 𝑡 = 1,         0 < 𝑡 ≤ !!!𝐸𝑒!!"!! !!!!! 𝐻(𝑡 − !!! ),         𝑡 > !!!                                   ... Equation 2-2 
where T0 is the appearance time of contrast agent in the brain relative to that in the input 
artery, Vb (or CBV) is the volume of contrast distributed in the intravascular space, 𝐸 = 1− 𝑒!!"!  is the extraction fraction, and H is the unit step function. As shown in 
Equation 2-2, R(t) of the JWL model is parameterized by F (or CBF), PS, Vb (or CBV), 
and Ve, the distribution volume in the tissue.  CT Perfusion 5 (a prototype of CT 
Perfusion 4D, GE Healthcare, Waukesha, Wis) was used to estimate and generate 
parametric maps of PS, CBF, and CBV, by iteratively changing their values until an 
optimum fit to the tissue time density curve, Q(t) is reached according to Equations 2-1 
and 2-2. 
2.2.6 CT Perfusion Map Analysis 
CT Perfusion derived PS map was used to measure the increase in endothelial PS 
following FUSwMB. An elliptical region of interest (ROI) with an area of 20 mm2 was 
placed over the center of the FUS target to cover the focal zone of the transducer, and the 
control ROI was defined as a duplicate in the contralateral hemisphere. The FUS 
transducer focal zone was defined as 3 dB of intensity pressure, and had a cross sectional 
focal area of approximately 10 mm2 and a volume of approximately 33 mm2. The 
sonicated and control ROIs defined on the PS map from the baseline study were 
superimposed on the follow-up maps, after the different studies were manually registered 
using the skull and vascular markers. 
2.2.7 Histology 
Following CT Perfusion imaging, the rabbits were anaesthetized using 5% Isofluorane for 
2 minutes, euthanized by 3 ml of intravenous potassium chloride, then perfusion fixed 
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with 4% paraformaldehyde before the brain was removed intact and left in a 10% 
formalin solution until histological analysis. For gross histological analysis, the brains 
were coronally sliced into 4-mm thick sections using a rabbit brain matrix (ProTech 
International, Lowell, NC) visually assessed for EB dye leakage as confirmation of BBB 
disruption and hemorrhagic lesion for tissue damage. For three representative rabbits, the 
sonicated slices were embedded in paraffin, sliced into 20-µm sections, stained with 
hematoxylin and eosin (H&E), and the sonicated regions examined under a microscope.  
2.2.8 Statistical Analysis 
The difference in the likelihood of lesions between cases with applied powers of 1.0 W or 
above, compared with applied powers between 0.5 – 0.6 W with sonication time of 150 – 
180, or with sonication time of 120 s or less were assessed using Fisher’s Exact test, with 
Bonferroni correction applied to account for 3 comparisons (m = 3). For statistical 
comparison of the effects of varying applied energy on the dynamics of the induced 
disruption, all the sonications with a sonication time of 180 s were retrospectively 
grouped into those that caused visible lesions from histology (n=8), and those that did not 
(n=4). The differences in CT Perfusion derived PS between time points were assessed 
using Mann-Whitney U Tests, with Bonferroni correction applied to account for 3 
comparisons (m = 3), comparing baseline with the peak PS and 180 min post, and the 
peak PS with 180 min post. The peak PS was defined as the time point when the highest 
PS following FUSwMB was measured. Regression analysis was used to investigate the 
correlation between Eapplied and PS. Akaike’s information criterion (AIC) was then used 
to test which regression model (linear vs. exponential) provides the best model fit. 
Logistic regressions were also used to investigate the association between the presence of 
EB leakage with PS at the peak and at 3 hours post sonication, the presence of a lesion 
with PS at the peak and at 3 hours post sonication, the presence of EB leakage with 
applied sonication power and Eapplied, and the presence of a lesion with applied sonication 
power and Eapplied. Significance was determined for rejecting the null hypothesis that the 
area under the curve (AUC) for the receiver operator curve (ROC) was equal to 0.5. 
Statistical significance was determined as p < 0.05 for all analyses. All statistical analyses 
were performed with IBM SPSS v23. 
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2.3 Results 
The first goal of the study was to confirm BBB disruption using Gd enhanced T1-
weighted MRI in two rabbits, before quantitative evaluation of BBB with CT Perfusion. 
Both rabbits were sonicated at 3 W for a duration of 180s. Figure 2-3 shows the 10-
minute post MR images in the coronal, axial, and sagittal planes, and the 40-minute post 
axial BBB PS maps for the sonicated. The 40 minute post BBB PS over the sonication 
region measured from the corresponding functional maps were 3.9 and 4.5 ml/min/100g 
for rabbits 1 and 2, respectively. At the same timepoint, the untreated contralateral 
hemisphere BBB PS was 0.0 for both rabbits.  
The second goal of this study was to titrate the applied power and sonication time to 
identify a range of values that can induce a transient increase in BBB permeability, with 
minimal or no injury in a rabbit model. Table 2-1 summarizes the results for rabbits 3 to 
16 including exposure parameters, BBB PS at baseline, the peak, and 180 min post, 
Eapplied and gross histology results. These experiments started with an applied power of 
3.0 W at a constant sonication time of 180 s. Then the applied power was reduced down 
to a range of 0.5 – 0.6 W, after which the sonication time was reduced from 180 s to 30 s. 
All 6 cases with an applied power of 1.0 W or above demonstrated lesions at gross 
histological analysis. When the applied power was 0.5 – 0.6 W and the sonication time 
between 150 – 180 s, the incidence of lesions dropped to 6 out of 10, which was not 
significantly different than 1.0 W or above (p = 0.1). Only 1 out of 10 cases with 0.5 – 
0.6 W applied powers and sonication times of 120 s or less resulted in lesions, which was 
less likely than sonication times between 150 - 180 (p < 0.03, but not significant after 
Bonferroni correction), and less likely than all cases with an applied power of 1.0 W or 
above (p < 0.005, remained significant after Bonferroni correction). All the 13 cases that 
demonstrated lesions also showed signs of EB leakage, but there were 3 cases in which 
EB leakage was observed in the absence of lesions on gross histology. 
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Table 2-1: Summary of Focused Ultrasound (FUS) exposure parameters including 
applied power, sonication time, and total sonication energy (Eapplied), as well as 
permeability surface area product (PS) and gross histology results. 
Rabbit Power (W) Time (s) 
Eapplied 
(J) 
PS Baseline 
(ml/min/100g) 
PS at Peak  
[time of Peak] 
(ml/min/100g) 
PS 3 hrs post 
(ml/min/100g) 
Lesion/ 
Hemorrhage 
EB 
leakage 
3 3.00 180 5.40 0.0 9.4 [5 mins] 3.4 Yes Yes 
4 3.00 180 5.40 0.0 13 [5 mins] 6.6 Yes Yes 
5 3.00 180 5.40 0.0 6.9 [15 mins] 5.5 Yes Yes 
6 2.00 180 3.60 0.2 6.3 [5 mins] 3.1 Yes Yes 
7 1.50 180 2.70 0.1 6.4 [5 mins] 3.1 Yes Yes 
8 1.00 180 1.80 0.3 8.5 [5 mins] 6.2 Yes Yes 
9 0.50 180 0.90 0.1 1.1 [15 mins] 0.1 No No 
10 0.60 180 1.08 0.0 1.1 [15 mins] 0.1 No No 
11 0.60 180 1.08 0.3 2.4 [15 mins] 0.7 No Yes* 
12 0.60 180 1.08 0.0 4.1 [5 mins] 0.9 Yes Yes 
13 0.60 180 1.08 0.2 1.8 [30 mins] 0.1 No Yes* 
 0.55 180 0.99 0.1 5.2 [15 mins] 2.6 Yes Yes 
 0.60 150 0.90 0.2 4.7 [30 mins] 2.7 Yes Yes 
 0.55 150 0.83 0.1 3.3 [15 mins] 1.0 Yes Yes 
14 0.55 150 0.83 0.1 3.9 [30 mins] 3.0 Yes Yes 
 0.50 150 0.75 0.0 4.0 [30 mins] 3.4 Yes Yes 
 0.55 120 0.66 0.1 2.1 [30 mins] 1.4 Yes Yes 
 0.50 120 0.60 0.1 1.2 [15 mins] 0.3 No Yes* 
15 0.60 120 0.72 0.1 0.4 [15 mins] 0.2 No No 
 0.60 90 0.54 0.1 0.2 [30 mins] 0.2 No No 
 0.60 60 0.36 0.1 0.3 [15 mins] 0.3 No No 
 0.60 30 0.18 0.1 0.2 [15 mins] 0.2 No No 
16 0.55 120 0.66 0.2 0.9 [5 mins] 0.1 No No 
 0.55 90 0.50 0.1 0.6 [15 mins] 0.2 No No 
 0.55 60 0.33 0.1 0.5 [15 mins] 0.1 No No 
 0.55 30 0.17 0.1 0.1 [15 mins] 0.1 No No 
* Cases showed EB leakage without any visible tissue damage 
To better investigate the effect of total applied sonication energy (Eapplied), the peak PS 
values were plotted against it in Figure 2-4. The sonications were identified by the 
presence of lesions (red) and no lesion (blue) at gross histology, and sonication times less 
than 120 s (triangles), or 150 and 180 s (circles). Eapplied and peak PS showed a stronger 
fit with an exponential curve (R2 = 0.62) than a linear relationship (R2 = 0.40). The AIC 
determined that the exponential regression was a significantly better fit than the linear 
regression (p < 0.005). 
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Figure 2-3: Gadolinium (Gd) enhanced T1-weighted magnetic resonance imaging 
(MRI) in multiple planes and blood-brain-barrier (BBB) permeability surface area 
product (PS) maps for two rabbits that demonstrated BBB disruption. In MR 
images, the regions of increased BBB permeability are indicated with blue arrows.  
For the group that demonstrated lesions over the sonicated region (lesion group), the 
BBB PS at the peak (7.5 ± 3.1 ml/min/100g; p < 0.0005, significant after Bonferroni 
correction), and at 180 min post (4.1 ± 2.1 ml/min/100g; p < 0.0005, significant after 
Bonferroni correction) were significantly higher than baseline (0.1± 0.1 ml/min/100g). 
The BBB PS at the peak was also significantly higher than that at 180 min post (p < 
0.0005, significant after Bonferroni correction). For the group that did not demonstrate 
any lesions over the sonicated region (non-lesion group), the BBB PS was significantly 
higher at the peak (1.2 ± 1.1 ml/min/100g; p < 0.005, significant after Bonferroni 
correction), when compared to baseline (0.1 ± 0.1 ml/min/100g), and the BBB PS at the 
peak was significantly higher than at 180 min post (0.3 ± 0.3 ml/min/100g; p < 0.005, 
significant after Bonferroni correction). However, there was no difference in BBB PS 
between baseline and 180 min post (p = 0.2). These differences can be visualized in the 
averaged BBB PS time curves for both the lesion and non-lesion groups, presented in 
Figure 2-5. The time series of BBB PS maps of the sonicated slice for a representative 
rabbit that demonstrated a transient disruption, and displayed EB leakage without any 
visible lesions is shown in Figure 2-6. 
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Figure 2-4: Total applied sonication energy (Eapplied) plotted against peak 
permeability surface area product (PS) for all sonications with 0.5 – 0.6 W applied 
power. The sonications are grouped by the presence of lesions (red) or no lesions 
(blue) at gross histology, and sonication times of 120 s or less (circles), or 150 and 
180 s (triangles). 
Receiver operating curve (ROC) analysis found that peak PS (AUC = 0.994, p < 0.001; 
AUC = 1.000, p < 0.005) and 3-hour post PS at sonication (AUC = 1.000, p < 0.001; 
AUC = 0.950, p < 0.005) are strong predictors of EB leakage (Figure 2-7a) and presence 
of a lesion (Figure 2-7b) respectively. ROC analysis also found that Eapplied (AUC = 
0.849, p < 0.005) was a predictor of the presence of EB leakage, but applied sonication 
power (AUC = 0.675, p = 0.1) was not (Figure 2-7c), and that Eapplied (AUC = 0.891, p < 
0.005) was a predictor of the presence of a lesion, but applied sonication power (AUC = 
0.644, p = 0.2) was not (Figure 2-7d). 
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Figure 2-5: The average blood-brain-barrier (BBB) permeability surface area 
product (PS) vs. time curves for the sonicated and contralateral (control) 
hemispheres in the rabbits, grouped by those that demonstrated visible lesions over 
the sonicated region at gross histology (n=8), and those that did not (n=4).  Error 
bars indicate standard deviations. *Significantly different from baseline value as 
determined by paired t-tests with Bonferroni correction for multiple comparisons.   
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Figure 2-6: The coronal blood-brain-barrier (BBB) permeability surface area 
product (PS) maps over time for a rabbit sonicated for 180s at an applied acoustic 
power of 0.6W that demonstrated reversible increased BBB permeability, Evans 
Blue (EB) dye leakage, and no visible lesions over the sonicated region. 
Figure 2-8 shows the coronal BBB PS maps and gross histology findings from three 
rabbits. The first case had a peak PS of 1.1 ml/min/100g, but did not indicate EB leakage 
or lesions at gross histology; the second case had a peak PS of 2.4 ml/min/100g, showed 
EB leakage, but did not show any lesion; and the third case which had a peak PS of 8.5 
ml/min/100g, showed EB leakage and lesions. In addition, tissue sections from the cases 
presented in Figure 2-8 were stained with hematoxylin and eosin (Figure 2-9) to 
investigate the vascular and tissue effects over the range of induced BBB disruption. 
With sonication at 0.5 W (Figure 2-9a,d) and 0.6 W (Figure 2-9b,e) there were no 
observed lesions over the sonicated region. With sonication at 1 W (Figure 2-9c,f) there 
were regions of scattered microhemorrhages without neuronal degeneration (Figure 2-
9g), more severe hemorrhagic regions accompanied by selective neuronal necrosis 
(Figure 2-9h), and ischemic regions accompanied by neuronal necrosis (Figure 2-9i) 
dispersed over the sonicated region.  
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2.4 Discussion 
Our study demonstrates the feasibility of using CT Perfusion derived BBB PS 
measurements as a tool for measuring the increased PS response following FUSwMB. 
The first goal of this study was to qualitatively confirm the BBB disruption using Gd-
enhanced T1-weighted MRI, before using CT Perfusion to obtain quantitative BBB PS 
measurements (Figure 2-3). The better quantitative accuracy of CT over MRI techniques 
relative to changes in contrast concentration provides greater confidence in tracer kinetic 
model derived measures of PS (30,31). The goal for the second part of the study was to 
optimize the exposure parameters to obtain a transient BBB disruption with minimal or 
no damage to the tissue and vasculature. Our results demonstrate a range of exposure 
values that can be used to induce transient BBB disruption in a rabbit model without 
adverse vascular and tissue effects.  
The optimal power and sonication time for no adverse effects were 0.5 – 0.6 W and 120 s 
respectively. As the power and sonication times were increased, the likelihood of 
inducing lesions began to increase. Logistic regressions found that the total applied 
sonication energy (Eapplied = Power x time) was a predictor of lesion and EB leakage, but 
power by itself was not.  Histological analysis (Figure 2-9) of the lesions in the sonicated 
region revealed scattered micro- and more severe hemorrhages, some accompanied by 
neuronal injury, and signs of ischemia. A study by Chopra et al. investigating the effects 
of FUS exposure parameters on BBB disruption in rabbits found similar results (16). 
They showed that for applied power between 0.5 and 4.5W at sonication times of 180 s or 
above, hemorrhages or lesions accompanied by neuronal injury were seen in all cases, the 
incidence of which decreased as sonication time was decreased.   
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Figure 2-7: Receiver operating Curve (ROC) and the corresponding area under the 
curves (AUC) for logistic regressions of Evans Blue (EB) leakage with (a) peak 
permeability surface area product (PS) and 3-hour post PS; the presence of a lesion 
with (b) peak PS and 3-hour post PS;  (c) the presence of EB leakage with applied 
sonication power and energy, and (d) the presence of a lesion with applied 
sonication power and energy. The p-value indicates the significance of rejecting the 
null hypothesis that AUC = 0.5.   
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The relationship between Eapplied and the peak PS was used to evaluate the combined 
effect of the applied power and sonication time on the induced BBB disruption (Figure 2-
4). The fit between Eapplied and peak PS was found to be stronger as an exponential curve 
(R2 = 0.62) as opposed to a linear relationship (R2 = 0.40). This indicates that there 
appears to be a threshold at which increased exposure parameters begin to rapidly 
increase the extent of BBB disruption with respect to Eapplied. We also found that as the 
induced PS increases, whether at the peak or at 3 hours post, the likelihood of causing 
tissue effects also increases.  This agrees with earlier studies (14,16). 
Since the MB was administered intravenously, recirculated bubbles were present 
throughout the sonication period, as their concentration gradually decreased over the 180 
s. Chopra et al. 2010 has previously reported that as the sonication time increases, MB 
decay results in a plateau of effectiveness in BBB disruption. Goertz et al. 2010 has 
reported that the decay in MB concentration over time results from FUS cavitation as 
well as vascular clearance, and can be substantially influenced by FUS exposure 
parameters. Although we assumed the MB decay remained constant with different 
exposure parameters used in our study, these prior findings highlight the importance of 
monitoring the temporal concentration of MB agents at the FUS targeted regions when 
optimizing FUS induced BBB disruption.  
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Figure 2-8: Blood-brain-barrier (BBB) permeability surface area product (PS) maps 
at 15 min post sonication and gross histology results for 3 cases using acoustic power 
of 0.5 – 1.0 W and the same sonication time of 180 s. 
All the sonications with a time of 180 s (n=12) were retrospectively grouped into those 
that showed lesions from gross histology, and those that did not. Induced BBB disruption, 
by FUSwMB, in cases that did not result in any lesions was transient in nature- the 
increased PS returned to baseline level at around 3 hours post sonication – indicating a 
distinct therapeutic window for increased drug delivery in the sonicated region that can 
be monitored using CT Perfusion (Figures 2-5 and 2-6). For the cases in which lesions 
were observed, the BBB PS remained significantly elevated when compared to baseline, 
up until the animals were sacrificed at 5 hours post sonication.  
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Figure 2-9: Hematoxylin–eosin (H&E) stained tissue sections (a-c) for the 3 cases 
shown in Figure 2-8.  The middle (d-f) is 10X magnification for corresponding 
sections (a-c). The bottom row is 120X magnification of distinct pathologies in the 
case sonicated at 1.0 W (c & f): (g) regions of scattered microhemorrhages without 
neuronal degeneration (short arrows), (h) more severe hemorrhagic regions 
accompanied by selective neuronal necrosis (dark-stained neurons, long arrows), 
and (i) ischemic regions accompanied by neuronal necrosis (hollow arrows). 
Figure 2-8 shows the BBB disruptions in three rabbits at applied sonication powers of 0.5 
W, 0.6 W, and 1.0 W respectively, while sonication times were kept at 180 s. EB in blood 
binds to serum albumin, which has an average molecular size of about 65,000 Da, and 
other large proteins such that EB extravasation is an indicator of BBB permeability to 
molecules significantly larger than our contrast agent, which is around 760 Da. This 
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result suggests that the BBB disruption induced by FUSwMB facilitates delivery of both 
small and large molecules. 
When blood flow (F) is at least 5 times greater than permeability (PS), the flow extraction 
product (FE) can be approximated by PS, in which case PS can be interpreted as the 
unidirectional flux of solutes from blood plasma to parenchymal tissue in a unit mass of 
tissue, and is expressed in units of ml/min/100g. Stated in another way, PS is the volume 
(mL) of blood that is completely cleared of contrast per minute in a unit mass of tissue by 
transfer to the interstitial space. As such, the area under PS x drug concentration vs time 
curve would give the amount of drug delivered to a volume in the brain. This estimation 
is important not only for accurately quantifying drug delivery in clinical trials, but also to 
monitor the treatment effect from BBB disruption on the patient in the clinical case.  
Endothelial permeability, P, is dependent on both the number of endothelial pores and 
their size. Given the endothelial pore size, permeability is inversely related to the square 
root of molecular weight (MW) of a molecule (32).  
Then: 
 !!!! = !"!!"!                                                                … Equation 2-3  
 
Using this relationship PS measured at one molecular weight can be scaled to that for a 
different molecular weight.  Future histological studies using fluorescent-tagged markers 
of different molecular weights can validate this relationship between PS and the 
molecular weight of permeable solutes.  
The data in Table 2-1 shows that the minimum peak PS value that showed signs of EB 
extravasation was 1.2 ml/min/100g. There were also two instances of a peak PS value of 
1.1 ml/min/100g that did not show any EB extravasation. From our data set, we can 
assume that a PS of 1.2 ml/min/100g is the threshold contrast PS that will allow serum 
albumin bound EB to pass through the FUSwMB disrupted BBB. This study found that 
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both peak and 3-hr post PS were strong predictors of EB leakage and lesions, indicating 
that PS is sensitive enough to monitor both the extent of BBB disruption, and the safety 
of the procedure. 
Our findings were consistent with previous studies that have attempted to estimate BBB 
PS permeability using DCE-MRI through calculation of Ktrans (24,25). In the study by 
Park, 30 s pulsed sonications with MB administration were applied at exposure 
parameters that had previously been shown to be safe and cause minimal vascular 
damage - 0.3 to 0.54 W with 10ms bursts at 1% duty cycle - increased permeability in the 
sonicated hemisphere to at least an order of magnitude higher than contralateral 
hemispheres. Doxorubicin delivery was also evaluated in this study and showed a 101 % 
increase in the sonicated region over the control hemisphere. When Ktrans was plotted 
against doxorubicin delivery over the sonicated regions, a correlation was observed with 
r=0.7 (24). Our future studies will also look to correlate the delivery of 
neurothereapeutics with measurements of PS, as a quantitative marker of drug delivery 
across the BBB. 
A major limitation with using FUSwMB to induce BBB disruption was the variability in 
the induced BBB disruption, even when sonications with similar exposure parameters, 
MB dose, and skull thickness were used. Because of the narrow window for which BBB 
disruption can be safely achieved, it is important to develop mechanisms to adequately 
control the sonications. Without this control, FUS exposure can either impart excessive 
forces on the MB resulting in inertial cavitation which is associated with vascular and 
tissue damage (33), or lead to very small oscillations that are insufficient to induce BBB 
disruption (34). Recently, the use of real-time acoustic emissions feedback to monitor 
MB behavior on a burst-by-burst basis has been used to control the harmonics of FUS, by 
adjusting exposure parameters to avoid those signatures. Spectral content and the strength 
of emissions can be used to search for harmonic (35) or ultra-harmonic (36) emissions 
that are indicative of stable cavitation, and therefore a safe and controlled BBB 
disruption.  
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2.5 Conclusions 
This study demonstrates that CT Perfusion is a promising tool for monitoring and 
measuring the increased BBB PS, following FUSwMB. We present a range of exposure 
parameters, power and sonication time, that cause transient BBB disruption with and 
without visible brain injury, in a rabbit model. The PS vs. time profiles allow for the 
visualization of the distinct window for increased drug delivery following sonication. 
More importantly, we determined that the threshold contrast PS of ~ 1.2 mL/min/100g 
would allow serium albumin bound EB dye (~65 kDa) to leak across the FUSwWB 
disrupted BBB. As this was a pilot study with the goal to determine FUS sonication 
exposure parameters to induce transient and measurable BBB disruption with little or no 
damage to the vasculature or tissue, it is limited by the number of animals and the range 
of exposure parameters used. Future studies can investigate the relationships among the 
induced PS over time, delivery of different agents, and treatment efficacy for various 
disease models with prospective study designs. 
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Chapter 3  
3 Comparison of Small (760 Da), and Large (65 kDa) 
Contrast Agent Dynamic Contrast-Enhanced Computed 
Tomography to measure Blood-Tumor-Barrier 
Permeability Surface Response Following Focused 
Ultrasound Sonication with Microbubble Administration 
in a C6 Rat Glioma Model 
3.1 Introduction 
Despite the aggressive treatment regime of surgical de-bulking, radiotherapy, and/or 
chemotherapy administration, brain tumor remains a difficult challenge because of high 
rates of recurrence and mortality. Recent interest in therapeutic targeting of angiogenesis 
has led to the development of bevacizumab, a humanized monoclonal antibody targeting 
vascular endothelial growth factor (VEGF), which has demonstrated significant responses 
on magnetic resonance imaging (MRI) among patients with recurrent tumors in phase II 
clinical trials (1,2). After FDA approval however, two placebo-controlled, randomized 
trials that combined bevacizumab with the best standard of care for newly diagnosed 
glioblastoma (GBM) - radiotherapy and temozolamide, showed a 3-to-4 month 
prolongation of progression free survival, but no significant effect on overall survival 
(3,4). 
As a monoclonal antibody, bevacizumab is a relatively large molecule, with a mass of 
approximately 149 kDa. Because of its size, delivery across the blood-tumor-barrier 
(BTB) remains a concern, and needs to be addressed when investigating its efficacy. The 
dilemma is that while increasing the dose delivered to the tumor may improve treatment 
outcomes, it will also likely result in substantial systemic toxicity (5). Therefore, it is 
critical to develop techniques for delivering chemotherapeutic agents across the BTB, 
such that a sufficiently high therapeutic dose can be delivered to the tumor, while dose to 
normal brain and the rest of the body is minimized (6). 
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In brain tumors, and particularly in GBM, BTB breakdown is highly heterogeneous 
within the tumor, resulting in highly variable permeability within different areas of the 
same tumor (7). The success of chemotherapy is hampered by these intratumoral 
heterogeneities (8), especially in areas where the ‘incompletely disrupted’ blood-brain-
barrier becomes an obstacle for optimal delivery of chemotherapeutics to the tumor. 
Another challenge in treating brain tumors is its infiltrative nature, as tumor cells can 
migrate great distances from the periphery of the tumor (9) and this migration is partly 
responsible for the high rate of GBM recurrence (10,11). Tumor cells tend to invade 
individually or in small groups, where they co-opt existing blood supplies for oxygen and 
nutrients, rather than growing their own de-novo (12). Because of these micro-invasions, 
using radiotherapy to eradicate diffuse infiltrative glioma, without significantly 
increasingly the toxic effects of treatment from the greater mass of normal tissue 
irradiated, is difficult to achieve (13,14).  
The intact and functional blood-brain-barrier (BBB) is typically permeable only to lipid 
soluble small molecules with a molecular mass of less than 400 Da (15). As GBM 
progresses, increased BTB permeability result in vasogenic edema from plasma that leaks 
into the tumor and surrounding brain (16,17). This together with uncontrolled 
proliferation of tumor mass are often accompanied by elevated interstitial fluid pressure 
(IFP) in the tumor (18,19).  In the context of drug delivery, elevated IFP is another 
barrier, particularly for larger molecules such as bevacizumab that are less able to 
passively diffuse across the BTB (20,21). It can be hypothesized that such large 
molecules have to rely more on the transvascular pressure gradient for convective flux 
across the barrier, as opposed to passive diffusion. For this reason, it is important to 
consider the delivery mechanisms of both small (diffusion and convection) and large 
molecules (more convection than diffusion) when assessing the tumor microenvironment 
and transport of a desired chemotherapeutic agent in GBM treatment.  
Several BTB permeability-enhancing strategies have been used to increase the delivery 
and accumulation of drugs within the tumor core and periphery, and can generally be 
classified into three groups: 1) physically circumventing the BTB, 2) pharmacologically 
opening the BTB, and 3) increased site-specific delivery across the BTB. The first 
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approach involves direct delivery into the tumor, bypassing systemic circulation, and 
involves techniques such as direct intratumoral injection (22), implanting drug-releasing 
polymers (23), convection-enhanced delivery (24), and intranasal delivery (25). The 
second approach, which involves enhancing BTB permeability with hypertonic mannitol, 
alkylglycerols, or a bradykinin analog (11), has been associated with better therapeutic 
outcomes, but has unacceptable high rates of complications due to lack of specificity 
(26). The third approach effects localized and transient disruption of the BBB  with 
techniques such as focused ultrasound, photodynamic therapy, and photochemical 
internalization, with minimal damage to the surrounding brain (27).  
In the last decade, pre-clinical studies using focused ultrasound (FUS) sonications with 
intravenously injected microbubbles (MB) have demonstrated the increased delivery of a 
range of imaging tracers and therapeutic agents across the BTB. These include small 
molecules such as Temozolomide, 194 Da (28,29), and Carmustine (BCNU), 214 Da 
(30), imaging contrast such as Gadolinium-DTPA (Gd-DTPA), 938 Da (31–33), 
monoclonal antibodies such as Trastuzumab, 145 kDa (34), and liposomal Doxorubicin, 
80-90nm (33,35,36). For the translation of this technique into clinic, it is important to 
evaluate the dynamics and safety of enhanced drug delivery across the BTB from FUS 
sonication with MB administration (FUSwMB). Therefore, the purpose of this study is to 
investigate using dynamic contrast-enhanced computed tomography (DCE-CT), also 
known as CT Perfusion, the change in BTB transport of a standard small, Isovue (760 
Da), and large, eXia (65 kDa), contrast agent up to 72 hours following a single episode of 
FUSwMB.  
3.2 Methods and Materials 
3.2.1 Study Protocol and Experimental Groups 
All experiments were approved by the Animal Use Subcommittee of the Canadian 
Council on Animal Care at our institution. Fifteen male Wistar rats (300-450g) were used 
in this study. For each rat, 1x106 C6 glioma cells were surgically implanted into the right 
striatum of the brain, using a stereotactic frame, with coordinates 3 mm to the right, and 1 
mm posterior to the center of the bregma, along the coronal suture. Follow-up CT 
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Perfusion scanning was performed at day 7 post implant, and every 2 days after that, until 
the following criteria were met at 8-15 days after implantation: 1) the tumor was greater 
than 3 mm in diameter, measured using the average CT image map (derived by averaging 
all images of the same slice in the CT Perfusion study), and 2) the tumor permeability 
surface-area product (PS) was greater than 1 ml/min/100g, at which time the tumors 
underwent FUSwMB.  Anesthesia was induced with 2.5% isoflurane using a nose cone, 
before the head was shaved and depilated, and a tail vein catheter was inserted. 
Ketamine-xylazine (10:1) was then administered at a rate of 5-10 ml/hr via the tail vein 
catheter as isofluorane was turned off. A baseline CT Perfusion scan was performed 20 
minutes after switching isofluorane off, then the rat was placed on the FUS system inside 
the CT gantry and the tumor underwent FUSwMB under CT image guidance. The 
animals were separated into an acute group (n=5), where repeat CT Perfusion scans were 
performed at 0.5, 1, 2, 3, and 4 h post sonication, and a recovery group where the animals 
were recovered at 1 hour following sonication, and follow-up CT Perfusion scans were 
performed at 24 and 72 h post (n=10). Animals in the acute group were also sonicated in 
the contralateral hemisphere as a control for normal BBB response. Following the final 
follow-up scan, the rats in both acute and recovery group were sacrificed with 
intravenous administration of potassium chloride solution. 
3.2.2 Focused Ultrasound Sonication with Microbubble 
Administration 
The rat was placed supine on the FUS system (RK100, FUS Instruments Inc., Toronto, 
Canada) and was carefully positioned for optimal trans-cranial sonication, with the 
transducer placed orthogonally to the surface of the head. A layer of ultrasound gel was 
applied to the skull prior to sonication, to allow for smooth transmission between water in 
the FUS system and the skull. A schematic of the experimental setup is shown in Figure 
3-1. With the rat on the FUS system, an axial CT scan (140 kVp, 200 mA, 1s rotation 
time, 2.5 mm slice thickness) was performed to locate the brain followed by a baseline 
CT Perfusion scan (see below for details) to locate the center of the tumor. These 
coordinates were then input into the FUS system to target the tumor center. All 
sonications were pulsed at 1 Hz, 0.5 W and a 10 ms burst length (1 % duty cycle) for 120 
82 
s. The transducer was spherically focused with a diameter of 75mm, a radius of curvature 
of 60mm, and operated at a frequency of 0.763 MHz. A single bolus of Definity 
(Lantheus Medical Imaging, USA) microbubbles in 1:10 saline dilution at a dose of 20 
µl/kg was manually injected via the vein catheter simultaneous with the start of 
sonication. In the case of multiple sonications, at least 5 minutes were allowed for 
clearance of MB between each episode of FUSwMB (37).   
 
Figure 3-1: Schematic of the experimental setup - the rat head was placed supine on 
the surface of the water tank, with the focal zone of the focused ultrasound 
transducer (FUS) aligned to the tumor. 
3.2.3 Dynamic Contrast Enhanced Computed Tomography 
Perfusion  
To quantitatively evaluate the BBB PS and other CT Perfusion derived parameters, a 
two-phase scanning protocol was used: first phase - two images per second acquired 
continuously for 30s with 80 kV, 250 mA, 0.5s rotation time, 2.5 mm slice thickness; 
second phase - one image acquired every 15s for another 180 seconds using the same 
scanning parameters. A 2.5 ml/kg bolus of 300 mg Iodine/ml (Isovue-300, 760 Da 
molecular weight), or a 2.5 ml/kg bolus of 160 ml Iodine/ml (eXia, Benitio Biomedical 
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Inc., 65 kDa molecular weight) was intravenously infused over 5 seconds at the start of 
the first phase. The acute group was only administered one Isovue CT Perfusion scan per 
time point, while the recovery group was administered an eXia scan first, followed by an 
Isovue scan after 10 min of clearance of eXia. 
3.2.4 Tracer Kinetic Modeling 
The Johnson-Wilson-Lee (JWL) distributed parameter model (38,39) was used to model 
the distribution of injected contrast in the brain (tumor) using permeability surface area 
product (PS), cerebral blood flow (CBF or F) and cerebral blood volume (CBV or Vb) as 
the model parameters. The technique is explained in detail in Chapter 1 (section 1.9.4) of 
this thesis. One internal carotid artery was identified in the CT Perfusion images and a 2 
x 2 pixel region was placed in the artery to generate the arterial time-density curve which 
was background subtracted to generate the arterial time-enhancement curve or the arterial 
input function, Ca(t) to JWL model. An arterial and the tumor time density curve from a 
rat study are shown in Figure 3-2. 
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Figure 3-2: Coronal head CT images of a rat following administration of contrast 
agent (Isovue).  Two slices of the head prior to FUSwMB are shown. A 2x2 voxel 
arterial input region of interest (ROI) and the corresponding arterial time density 
curve, Ca(t), along with tumor ROI and  corresponding tumor time density curve 
Q(t) are presented. 
Under the assumption that brain blood flow (F or CBF) is constant and CT measured 
signal in artery and brain is linear with respect to the concentration of contrast, the brain 
time-enhancement curve, Q(t) is the product of F and the convolution of the arterial input 
function and the impulse residue function R(t), as shown in Equations 3-1 and 3-2. 
   𝑄 𝑡 = 𝐹 ∙ [𝐶! 𝑡 ∗ 𝑅 𝑡 − 𝑇! ]                    … Equation 3-1 
  𝑅 𝑡 = 1,         0 < 𝑡 ≤ !!!𝐸𝑒!!"!! !!!!! 𝐻(𝑡 − !!! ),         𝑡 > !!!                      … Equation 3-2 
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where T0 is the appearance time of contrast agent in the brain relative to that in the input 
artery, Vb (or CBV) is the volume of ‘flowing’ blood that is in large vessels, arterioles, 
capillaries, venules, and veins, Ve is the distribution volume of contrast in the 
extravascular space, 𝐸 = 1− 𝑒!!"!  is the extraction fraction, or the fraction of mass that 
is transferred from the vascular to extravascular space during a single passage of blood 
from the arteriole end to the venous end of the capillaries of a tissue (40), and H is the 
unit step function.  
As shown in Equation 3-2, R(t) of the JWL model is parameterized by F (or CBF), PS, Vb 
(or CBV), and Ve.  CT Perfusion 5 (a prototype of CT Perfusion 4D, GE Healthcare, 
Waukesha, Wis) was used to estimate and generate parametric maps of PS, CBF, CBV 
and Ve, by iteratively changing their values until an optimal fit to Q(t) was reached 
according to Equations 3-1 and 3-2 for each voxel.  As discussed in Chapter 1, the 
volume transfer constant of solutes from blood to interstitial space is FE instead of PS 
(41). The relationship between FE and PS is given by the Equation 3-3: 
                               𝐹𝐸 = 𝐹(1− 𝑒!!"! )                        … Equation 3-3 
 
3.2.5 CT Perfusion Map Analysis 
The tumor was delineated using thresholds in the baseline PS, CBF, and CBV maps. A 
PS of over 1 ml/min/100g was used as the threshold for the tumor margin, as this value 
has previously been measured in high-grade brain tumors (42). Relative tumor CBF and 
CBV thresholds of 1.5x with respect to the contralateral hemisphere were also used to 
guide delineation of the tumor rim (43). An autologous control region in the contralateral 
hemisphere was also defined.  
For the acute group, PS, CBF, and CBV maps generated using Isovue contrast agent were 
analyzed to measure the acute response following FUSwMB. The tumor and control 
ROIs from the baseline maps were superimposed on the follow-up maps, after they were 
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manually registered together using the skull and vascular structures as landmarks 
(ImageJ, NIH).  
For the recovery group, both Isovue and eXia PS, CBF, and CBV maps were analyzed to 
measure the response up to 3 days following sonication. The tumor ROIs from the Isovue 
maps at each time-point were superimposed on the corresponding eXia maps, after the 
maps were manually registered together as in the acute studies. 
3.2.6 Statistical Analysis 
In the acute group, the differences in Isovue CT Perfusion parameters between time 
points were assessed using Mann-Whitney U Test, with Bonferroni correction applied to 
account for 3 comparisons (m = 3), comparing baseline with 30, 60 and 240 min post. 
Similarly, in the recovery group, the differences in Isovue and eXia CT Perfusion 
parameters between time points were assessed using Mann-Whitney U Tests, with 
Bonferroni correction applied to account for 3 comparisons (m = 3), comparing baseline 
with 1 h, 24 h, and 72 h post. Regression analysis was used to investigate the correlation 
between PS, CBF and CBV measured with both contrast agents at all time points. Bland-
Altman plots (44) were used to look at the agreement between Isovue and eXia CBF and 
CBV, with the range of agreement defined as mean bias ± 2 standard deviations. 
Statistical significance was determined as P < 0.05. All statistical analysis was performed 
with IBM SPSS v23.    
3.3 Results 
In the first 4 hours following FUSwMB in the acute group, the contralateral and tumor 
Isovue (760 Da) PS, CBF, and CBV over time is shown in Figure 3-3. For the 
contralateral region with intact BBB, the PS at 30 min post (1.1 ± 0.3 ml/min/100g) was 
significantly increased (p < 0.01, significant with Bonferroni correction) when compared 
to baseline (0.2 ± 0.06 ml/min/100g) before returning to baseline at 60 minutes post and 
thereafter. The tumor PS, which was elevated at baseline, did not show an immediate 
transient increase, instead decreased gradually over four hours following sonication.  
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The tumor PS was lower at 240 min post (3.9 ± 2.3 ml/min/100g; p < 0.03, not significant 
after Bonferroni correction) compared to baseline (5.9 ± 3.0 ml/min/100g). There were 
decreases in tumor CBF and CBV at 60 min post sonication (36 ± 14 ml/min/100g; p < 
0.03, not significant after Bonferroni correction) and (2.6 ± 0.8 ml/min; p < 0.02, 
significant after Bonferroni correction) when compared to baseline (60 ± 23 
ml/min/100g) and (3.4 ± 0.9 ml/min), respectively. Although not significant, there was a 
trend that tumor CBF and CBV remained suppressed compared to baseline out to 240 
minutes following FUSwMB. The contralateral CBF and CBV did not show any 
significant changes before and following sonication. Sequential PS, CBF, and CBV maps 
at baseline and following FUSwMB for a rat in the acute group are shown in Figure 3-4.  
 
	  
Figure 3-3: Serial tumor and control Isovue permeability surface area product (PS), 
cerebral blood flow (CBF), and cerebral blood volume (CBV) measured in the acute 
group before and over 4 hours following FUSwMB (n=5). *Significantly different 
from baseline as determined by Mann-Whitney U test (p < 0.05) after Bonferroni 
correction for multiple comparisons.  
 
88 
	  
Figure 3-4: Native CT Image, permeability surface area product (PS), cerebral 
blood flow (CBF), and cerebral blood volume (CBV) map for a representative 
animal in the acute group following FUSwMB.  Average tumor value is shown 
beneath each map. 
For the recovery group, tumor PS, CBF, and CBV using both contrast agents over time 
are shown in Figure 3-5. Tumor Isovue PS was significantly lower at 24 h post (6.3 ± 4.3 
ml/min/100g; P < 0.01, significant after Bonferroni correction) compared to baseline (9.6 
± 6.6 ml/min/100g), before returning back to baseline levels at 72 h post sonication (8.1 ± 
5.2 ml/min/100g; P = 0.08). In contrast to Isovue PS, there was a trend of increased 
tumor eXia PS at 24 h post (0.13 ± 0.13 ml/min/100g; P = 0.2) and 72 h post sonication 
(0.16 ± 0.14 ml/min/100g; P = 0.3), when compared to baseline (0.11 ± 0.09 
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ml/min/100g), although neither of these were significant. In addition, for the recovery 
group, Isovue CBF was higher at 24 h post (75 ± 30 ml/min/100g; P< 0.03, not 
significant after Bonferroni correction), but not at 72 h post sonication (69 ± 26 
ml/min/100g; P = 0.07) when compared to baseline (62 ± 19 ml/min/100g). Similarly, 
eXia CBF was higher at 24 h post (59 ± 18 ml/min/100g; P < 0.02, not significant after 
Bonferroni correction), but not at 72 h post (56 ± 17 ml/min/100g; p = 0.05), when 
compared to baseline (46 ± 7 ml/min/100g). Isovue CBV and eXia CBV at 24 h post (4.4 
± 1.3 ml/100g and 4.4 ± 1.2 ml/100g; both P < 0.03, not significant after Bonferroni 
correction) were both higher than baseline (3.8 ± 0.8 ml/100g and 3.5 ± 0.8 ml/100g) 
respectively, but those at 72 h post sonication (3.9 ± 1.0 ml/100g and 3.7 ± 0.9 ml/100g; 
P = 0.2 and P= 0.1) respectively, were not. A comparison of tumor Isovue and eXia PS 
maps for a representative subject at different time points in the recovery are shown in 
Figure 3-6.  
Figure 3-7 shows the correlations of tumor PS, CBF, and CBV measured with both 
contrast agents for all time-points as well as Bland-Altman plots investigating the 
agreement between Isovue and eXia derived CBF and CBV. When measurements from 
all rats were considered, there was no correlation of PS measured with Isovue and eXia (p 
= 0.3). Isovue and eXia CBF were moderately correlated (R2 = 0.63, m = 0.51; p < 
0.005), as were Isovue and eXia CBV (R2 = 0.48, m = 0.71; p < 0.005). Bland-Altman 
plots were used to investigate the agreement between Isovue and eXia derived CBF and 
CBV. The Bland-Altman analysis indicates that Isovue and eXia CBF had a mean bias of 
19.1 ml/min/100g, with the 95% limits of agreement ranging from -18.9 to 57.0 
ml/min/100g, while for CBV, the mean bias was 0.82 ml/100g, with 95% limits of 
agreement ranging from -2.34 ml/100g to 3.98 ml/100g.  
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Figure 3-5: Serial tumor permeability surface area product (PS), cerebral blood 
flow (CBF), and cerebral blood volume (CBV), measured with Isovue (760 Da), and 
eXia (~65 kDa), in the recovery group before and over 72 hours following FUSwMB 
(n=10). *Significantly different from baseline as determined by Mann-Whitney U 
test (P < 0.05) after Bonferroni correction was applied. 
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Figure 3-6: Permeability surface area product (PS) maps, measured with Isovue 
(760 Da), and eXia (65 kDa) contrast agents, for a representative animal in the 
recovery group before and following FUSwMB.  
3.4 Discussion 
This study uses CT Perfusion derived permeability surface product (PS) and perfusion 
measurements, from data obtained with a standard small (Isovue, 760 Da) and a large 
(eXia, ~65 kDa) molecular weight CT contrast agent to investigate the tumor response 
over 4 hours and over 3 days following FUSwMB in a C6 rat glioma model.  
The purpose of the first part of this study was to evaluate the tumor permeability surface 
product response over 24 hours following FUSwMB, at the same FUS exposure 
parameters, as determined in Chapter 2 of this thesis, which were titrated to induce 
transient BBB disruption in the normal brain with minimal damage. Surprisingly, the 
tumor Isovue PS, which was elevated at baseline, demonstrated a gradual decrease over 
four hours following sonication, instead of a significant immediate and transient increase 
that was seen with the intact BBB in Chapter 2.  
To expand on these findings, a second group of rats underwent FUSwMB, but were 
recovered from anesthesia at 1 h post sonication and underwent follow-up CT Perfusion 
studies at 24 and 72 h. post. We found that tumor Isovue PS remained decreased and was 
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significantly lower at 24 h post, compared to baseline, before returning to baseline levels 
at 72 h. 
	  
Figure 3-7: Comparison of Isovue (760 Da) and eXia (65 kDa) permeability surface 
area product (PS) for all 10 subjects (top left). Comparison of cerebral blood flow 
(CBF) for all 10 subjects (middle left with an identity line (red)), cerebral blood 
volume (CBV) for all 10 subjects (middle right with an identity line (red), and Bland 
Altman plots for agreement between Isovue and eXia measured CBF (bottom left), 
and CBV (bottom right) for all 10 subjects.  
This was an unexpected result as it contradicted results reported in previous pre-clinical 
studies. These studies can be grouped into those where the primary outcome was to 
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investigate tumor PS using imaging tracers, typically Gd-DTPA (29,31,32,33), or those 
that evaluate the delivery of chemotherapeutic drugs, and/or investigate its impact on 
clinical outcomes such as overall survival and tumor progression (28,30,32,34–36) 
following FUSwMB. When comparing FUS sonication studies that investigated tumor 
PS, using standard small molecule MRI imaging tracers, such as Gd-DTPA (molecular 
weight - 938 Da), it is important to note: 1) the time between tumor implant and 
sonication, in other words, the development stage of the tumor at the time of sonication, 
and 2) the time following sonication at which the follow-up PS and/or other perfusion 
parameters were measured. Details on these studies and their findings are summarized in 
Table 3-1. 
Table 3-1: Summary of pre-clinical studies that investigated tumor PS following 
focused ultrasound with microbubble administration (FUSwMB) (31,32,33). 
Author Glioma Cell 
line (Rat) 
Tumor 
Treatment Post 
Implant (days) 
Results 
Chu et 
al, 2013 
(31) 
C6 Glioma 
cells (Sprague 
Dawley rats) 
10   
 
17  
- Increased accumulation with R1 (immediately following 
sonication) 
- Did not increase accumulation with R1 (immediately 
following sonication) 
Yang et 
al, 2014 
(32)  
F98 Glioma 
cells (Fischer 
rats) 
8  
 
 
 
- Ktrans increased 2.46 times relative to untreated control 
(immediately following sonication) and 1.78 times relative 
to untreated control (24 h post sonication) 
Aryal et 
al, 2015 
(33)  
9L Glioma 
cells (Fischer 
rats) 
9 
14  
17  
- Ktrans increased (immediately following sonication) 
- Ktrans did not change (immediately following sonication) 
- Ktrans did not change (immediately following sonication) 
 
These studies indicated that in early stage tumors, defined as tumor treatment at between 
8 to 10 days post-surgical implant (31,32,33), FUSwMB did result in an immediate 
increase in Gd-DTPA tumor PS, and it may remain increased at 24 h post, albeit less than 
the peak immediately following sonication. In later stage tumors, however, there was no 
change in Gd-DTPA tumor PS immediately following FUSwMB. None of the studies 
investigated the tumor PS response over 3 days following sonication for late stage 
tumors, particularly at 24 h post when we observed a significant decrease in Isovue tumor 
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PS. Yang et al did investigate the increase in PS at 24 hours post, but only for tumors 
treated at day 8 post implant, not for late stage tumors.  
The sonication criteria for our study, which included a PS threshold of 1 ml/min/100g as 
high-grade tumor (42), resulted in sonication at 8 to 15 days post-surgical implant, 
highlighting the variability of tumor growth rates across different animals. To our 
knowledge, this study was the first that serially characterized the tumor PS response out 
to 3 days following FUSwMB. With our multiple time point studies, we showed that 
instead of increasing immediately following sonication, tumor Isovue PS gradually 
decreased up to 4 hours post sonication, and remains decreased at 24 hours post 
sonication. This observation was a previously unreported result. 
VEGF induced angiogenic proliferation and associated PS increase are hallmarks of 
glioma progression (45). Analysis of the three studies in Table 3-1 indicated that newly 
formed or early stage brain tumors did demonstrate an immediate transient increase in 
tumor PS to small molecular contrast agent following FUSwMB, however, this increase 
was attenuated in more developed or late stage brain tumors. This suggests that beyond a 
certain point in tumor development, FUSwMB is unable to enhance the already elevated 
tumor PS to small molecules in glioma.  
As brain tumor progresses, the elevated PS results in vasogenic edema and fluid 
accumulation which increase the interstitial fluid pressure (IFP) in and around the tumor 
leading to diminished transvascular pressure gradient required for convective delivery of 
solutes across the BTB (19,20,46,47). We hypothesize that the decrease in Isovue (760 
Da) PS up to 3 days following FUSwMB should also decrease the elevated IFP, restoring 
the transvascular pressure gradient required for the delivery and accumulation of larger 
molecules, such as bevacizumab, across the BTB. In the recovery group, CT Perfusion 
was performed first with a much larger molecular weight contrast agent, eXia (65 kDa), 
followed by the standard small molecular weight agent, Isovue (760 Da), at each time 
point before and after FUSwMB. The results showed that there was a trend towards 
increased eXia PS at 24 h and 72 h post, indicating that large molecule PS did increase 
after a decrease in small molecular (Isovue) PS in the 24-72 hr period following 
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FUSwMB. Although neither of these PS increases were statistically significant, they 
support the plausibility of our hypothesis and suggest further study is warranted. 
For both Isovue and eXia, CBF and CBV demonstrated an increasing trend at 24-h post 
FUSwMB, before returning to baseline levels by 72 h post, although these results were 
not significant. This finding, which is similar to outcomes seen with anti-angiogenic 
treatment (48–50), indicates that there was less edema and therefore, IFP, at 24-h post, 
allowing for a more ‘normalized’ perfusion across the tumor, further increasing drug 
delivery to and distribution throughout the tumor. 
Plausible mechanisms for the decrease in PS to small molecules such as Isovue, 
following FUSwMB may include: 1) destruction from MB cavitation of the newly 
formed and highly permeable angiogenic vessels which have significantly less pericyte 
coverage, leaving the more ‘normal’ and mature blood vessels functionally intact, or 2) 
FUS stimulates microglia in and around the tumor vasculature, temporarily restoring 
BBB function. Angiogenic tumor blood vessels go through a maturation process over 
time. Immature vessels in glioblastoma exhibit sparse pericyte coverage, compared to 
normal mature blood vessels in the brain (51), rendering them more susceptible to 
destruction by FUSwMB, whereas mature vessels with more pericyte coverage are 
protected against FUSwMB. In late stage tumors with proportionally more mature 
vessels, destruction of immature vessels by FUSwMB would lead to a decrease in PS, 
whereas in early stage tumors, there is an overwhelming number of immature vessels - 
the destruction of which is more than offset by the increase in vessel (endothelial) 
permeability, resulting in a net increase in PS.  
To test this hypothesis, rats in the recovery group were retrospectively grouped into the 
five lowest baseline PS (early stage), and those with the five highest baseline PS (late 
stage). We found that compared to baseline, the PS to small molecules for early stage 
tumors did not change at 24 h post, whereas in the late stage tumors, there was a 
significant decrease in PS at 24 h FUSwMB. This reinforces the conclusion that 
FUSwMB for developed or late stage tumors does not further elevate the PS, but instead 
may result in a decrease in PS following sonication. It has also been reported that reactive 
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astrogliosis is strongly correlated with glioma growth (52). Astrocytes become activated 
(proliferative), to varying degrees, in response to many CNS pathologies, including 
stroke, trauma, tumor growth, or neurodegenerative diseases (53,54). It is plausible that 
microglia in late stage tumors that demonstrate increased astrogliosis are stimulated by 
FUSwMB whereas those in early stage tumors are less affected in this respect. 
These results pose three interesting questions concerning drug delivery across the BTB 
following FUSwMB: 1) what benefit is there in terms of drug delivery, if the PS to small 
molecules is decreasing, instead of increasing? 2) How does one explain results that 
demonstrated FUSwMB prior to chemotherapeutic administration improved both drug 
accumulation (28–30,33) and clinical outcomes such as reduction in tumor volume and 
survival (28,30,33–35); and 3) In brain tumors, where the PS may be significantly 
elevated relative to F, can PS be used to approximate FE which governs drug delivery 
across the BTB? 
Before addressing these questions, it is important to understand the two underlying 
mechanisms by which drugs can cross the BTB: 1) diffusion, which is passive and 
dependent on concentration gradient across the barrier, and 2) convection, or bulk fluid 
flow carrying dissolved solute, across the barrier which is dependent on the hydrostatic 
pressure difference. A small molecule such as Isovue (760 Da) or Gd-DTPA (938 Da) 
has a relatively high diffusion coefficient; therefore its net flux is critically dependent on 
the diffusion coefficient before and after FUSwMB. Larger molecules, such as eXia (65 
kDa) and other targeted drugs such as trastuzumab (34) or liposomal doxorubicin 
(33,35,36), with much lower diffusion coefficients are less able to passively diffuse 
across the BTB and their net flux is dependent more on the pressure gradient across the 
fenestrae within the BTB. Given this consideration, it is plausible that following 
FUSwMB, small molecule PS (which approximates FE, the volume transfer constant) is 
decreased relative to before treatment, whereas the PS of larger molecules that are unable 
to diffuse across the BTB could behave differently- increase because of the reduction in 
IFP. For these larger molecules, it is the difference in hydrostatic pressure that governs 
convective solute exchange before and after sonication.  
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It is also important to consider the growth stage of the tumor, since the microenvironment 
is different between early and late stage tumors, influencing the degree of diffusion and 
convection before and following FUSwMB. In early stage brain tumors, small but not 
large molecule PS is elevated as new highly permeable angiogenic blood vessels are 
being formed, meaning only small molecules that are able to diffuse across the BBB/BTB 
are delivered, whereas the delivery of larger molecules that rely on convection is limited 
due to the small fenestrae in the endothelium. In later stage tumors, with markedly 
increased PS from pore sizes as high as 12nm (55), bulk fluid flow allows for hydrostatic 
pressure dependent convective solute exchange, delivering both small and large 
molecules into the tumor. 
Previous studies that demonstrated FUSwMB prior to chemotherapeutic administration 
improved both drug accumulation, and clinical outcomes, involved early stage tumors 
with small drugs such as Temozolomide - 194 Da (28,29) or BCNU - 214 Da (30), or 
larger molecules such as Trastuzumab – 145.5 kDa (34) or liposomal Doxorubicin - 80-
90nm (33,35,36). Aryal et al found that liposomal doxorubicin delivery was significantly 
enhanced following FUSwMB, compared to an untreated control, regardless of the stage 
of tumor growth, whereas Ktrans measured with Gd-DTPA (938 Da), was significantly 
elevated compared to controls treated at day 9, but not 14 and 17 (33). Our findings are in 
agreement with this result, demonstrating that for late stage tumors, FUSwMB may not 
increase small molecule PS, but instead allows for the increased delivery of larger 
molecules. In another study, Park et al found FUSwMB in combination with 
Trastuzumab, for six weekly treatments starting at 14 days following implant, resulted in 
better survival, with 4 out of 10 animals in which the tumor appeared to completely 
resolved (34). This study again highlights the potential for improved delivery, and 
therefore efficacy, for larger molecules following FUSwMB.  
When eXia and Isovue permeability surface products are plotted against each other for all 
time-points, there is no correlation between them (R2 = 0.03). Because of its large size, 
baseline eXia PS (0.1 ± 3.1 ml/min/100g) is almost 100 times smaller than baseline 
Isovue PS (9.6 ± 3.1 ml/min/100g), decreasing its measurement accuracy. Interestingly, 
when the animals with the 5 lowest Isovue permeability at baseline were removed from 
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the analysis, a weak negative correlation appeared (R2 = 0.15), suggesting that eXia 
permeability measurements for early stage tumors are not reliable because of the lack of 
convection, or bulk fluid flow, across the BBB/BTB. For late stage and highly permeable 
tumors with larger fenestrae within the BTB to allow for convection, eXia permeability 
can be measured more reliably. The negative correlation confirms our hypothesis that as 
the Isovue PS decreases over three days following FUSwMB, eXia PS, and therefore the 
delivery of large molecules such as bevacizumab, should increase. 
Although Isovue and eXia CBF were moderately correlated (R2 = 0.63, slope = 0.51), 
they were not in agreement with each other, with Isovue CBF being higher than eXia 
CBF. Isovue and eXia CBV were also moderately correlated (R2 = 0.48, slope = 0.71), 
but appeared to show better agreement than with CBF, with only 1 point outside of the 
95% limits of agreement. Because of its much larger size than Isovue, it is plausible that 
the higher viscous drag increases the mean transit time (MTT) to cross the vasculature, 
resulting in an underestimation of eXia CBF. 
A final point to address is whether PS, in practice, can be used to estimate FE which 
governs drug delivery across the BTB, especially for the current study. As discussed in 
Chapter 1, the volume transfer constant of solutes from blood to interstitial space is FE 
instead of PS.  The relationship between FE and PS is given by the following equation: 
 𝐹𝐸 = 𝐹 1− 𝑒!!"!                                                                                                            … Equation 3-3 
For the three regimes of exchange of solute between blood and interstitial space: 1) when 
PS<<F, the exchange is diffusion-limited and PS approximates FE accurately; 2) when 
PS is of the same magnitude as F, the exchange is neither diffusion nor flow limited and 
to determine the volume transfer constant both F and PS have to be estimated; and 3) 
when PS >>F, the exchange is flow-limited so that FE approaches F. Figure 3-8 plots the 
% error in using PS to approximate FE : 
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!"!!"!" ×100 = !" !!!! − 1 ×100                                     … Equation 3-4 
as PS is decreased relative to F.  
 
Figure 3-8: The percent error in using permeability surface area product (PS) to 
approximate the flow extraction product (FE), as shown in Equation 3-4, plotted for 
different ratios of F/PS. 
When PS is at least 5 times smaller than F (F/PS > 5.0), PS approximates FE to within 
10%; if this condition is not true, the error in approximating FE by PS rapidly increases.  
However, in brain tumors, where the BTB PS is significantly elevated (42), this condition 
may not be met. In this study, we found that whereas Isovue PS was significantly lower at 
24 h post, before returning to baseline at 72 h post; in contrast, the decrease in FE at 24 h 
post was not significant once the Bonferroni correction was applied, while FE at 72 h 
post remained significantly decreased compared to baseline. The BTB Isovue PS for 2 of 
the animals included in this study were on the threshold, suggesting that for such cases, 
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FE, which measures the volume transfer constant, would be the correct functional 
parameter to predict drug delivery across the BTB. 
There are limitations of this study that need to be discussed. The first was that tumors at 
different stages of growth were used in comparing vascular response to FUSwMB. 
Previous studies in the literature standardized FUS treatment at a set number of days 
following implantation. From our experience, C6 glioma cells grew (developed) at 
different rates following implantation, therefore even with this standardization it was 
difficult to control the growth stage at which tumors were sonicated. We attempted to 
circumvent this problem by standardizing on tumor size (diameter) but PS remained 
difficult to control. The second limitation was the difficulty is using a large molecular 
weight CT contrast, eXia to evaluate BTB PS. Since large molecular weight agents have 
limited transport across the BTB, the signal-to-noise of the brain time density curve was 
poorer, leading to decreased reliability of their PS measurement when compared to 
smaller molecular weight agents. Our reasoning that there should be increased PS and 
accumulation of large molecular weight drugs, such as bevacizumab (149 kDa), is 
dependent on the decrease in edema and IFP following the decrease in small molecules 
(including water) PS from FUSwMB treatment.  However, this study did not directly 
investigate edema. In chapter 4 of this thesis, we evaluate vasogenic edema by 
determining the extravascular contrast distribution volume (Ve) following sonication, as 
well as using MRI to investigate the water content in and around the tumor. 
Finally, there is evidence that the maximum delivery of NK cells across the BBB into 
tumors is achieved when the cells are injected just before the sonication (56,57), 
indicating the role of sonication in the delivery. Similarly, in study of Treat et al. (36), 
liposomal doxorubicin was injected prior to the sonications, and.showed survival benefit 
with just one treatment of implanted tumors, In our current study, only the delivery of 
agents after the sonications was considered. 
3.5 Conclusion 
In this study, we used CT Perfusion derived tumor PS response to both small and large 
molecular weight CT contrast agents acutely over 4 hours and sub-acutely over 3 days to 
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investigate the delivery of molecules of different sizes across the BTB following 
FUSwMB. Instead of an immediate transient increase that was seen with the normal 
BBB, the tumor PS measured with standard small Isovue (760 Da) contrast agent, which 
was abnormally elevated at baseline because of the breakdown of the BBB in tumor 
vasculature, demonstrated a gradual decrease up to 4 h following sonication, and 
remained decreased at 24 h post, before returning to baseline levels at 72 h. This 
unexpected result could be explained by the physical destruction of newly formed and 
highly permeable angiogenic vessels which lack pericyte coverage and/or by the 
stimulation of microglia in and around the tumor vasculature, highlighting the potential 
for FUSwMB to manipulate the tumor vasculature and its microenvironment, beyond 
simply opening the BTB. Furthermore, the decrease in Isovue PS for up to 24-72 hrs 
following sonication may be accompanied by a decrease in edema, and IFP, thereby 
increasing large molecular PS  and accumulation of larger chemotherapeutic agents, such 
as bevacizumab (149 kDa), that are unable to passively diffuse across the BTB and must 
rely on convective bulk solute flow. Future studies investigating enhanced delivery of 
small molecule drug to brain tumor using FUSwMB have to consider the tumor 
microenvironment, fenestra size in the BTB and mechanism of transport across the BTB 
for each drug. 
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Chapter 4  
4 Investigating the Decrease in Edema following Focused 
Ultrasound Sonication with Microbubble Administration 
using Magnetic Resonance Imaging and CT Perfusion 
Derived Extravascular Distribution Volume in a C6 Rat 
Glioma Model 
4.1 Introduction 
One of the hallmarks of Glioblastoma (GBM) progression is the loss of blood-brain-
barrier (BBB) integrity, leading to a permeable blood-tumor-barrier (BTB), accompanied 
by other pathological features - including marked angiogenesis with endothelial 
proliferation, severe hypoxia, and tumor necrosis (1–3). As a result, GBM vessels are 
tortuous, disorganized, and highly permeable, with abnormalities in the endothelial wall, 
pericyte coverage, and the basement membrane (4–7).  
The loss of BBB function results in the increased accumulation of fluid and plasma 
proteins peri-tumorally, and in the surrounding brain (8), leading to vasogenic edema, 
which by itself is a major cause of morbidity in brain tumors (9). Due to the lack of a 
lymphatic drainage system in the solid tumor mass, vasogenic edema results in an 
abnormal increase in interstitial fluid pressure (IFP), which creates a barrier for drug 
delivery , by diminishing the transvascular pressure gradient required for convective 
transport across the BTB barrier (10). 
At present, steroid  is the only treatment for controlling vasogenic brain edema, but with 
moderate efficacy and many side-effects (11). Recent pre-clinical and clinical studies 
have demonstrated that anti-angiogenic or anti-permeabilizing agents, such as 
bevacizumab or cediranib, may alleviate vasogenic brain edema by ‘normalizing’ the 
vasculature, creating a window of decreased permeability, and therefore decreased IFP, 
improving perfusion and drug delivery, particularly for large molecules that rely on 
pressure-dependent convective solute exchange across the BTB (8,12,13). Clinical 
studies also demonstrated that when anti-angiogenic agents are combined with 
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chemotherapy, they confer a synergistic beneficial effect for brain tumor treatment 
(14,15).  
In Chapter 3 of this thesis, we uncovered a decrease in endothelial permeability surface 
product (PS) response, as measured with a standard small molecule CT contrast agent, 
Isovue, out to 24 h following FUS sonication with MB administration (FUSwMB) in a 
C6 rat glioma model. We hypothesized that the observed decrease in endothelial 
permeability surface response should also be accompanied by a decrease in vasogenic 
edema, thereby decreasing the elevated IFP, restoring the transvascular pressure gradient 
required for convective fluid flux driven drug delivery across the BTB. In addition to 
improving drug delivery for larger drugs that are reliant on convective solute flux across 
the BTB, the potential to ‘normalize’ IFP using FUSwMB can be seen as a novel 
approach to alleviate the symptoms associated with vasogenic edema in brain tumors.  
The decrease in endothelial PS to small molecules of the tumor vasculature following 
FUSwMB was an unexpected and previously unreported result except for our publication. 
The exact mechanism for the transient restoration in BBB function is unclear, and could 
be explained by one of two following hypothesis: 1) Physical destruction of the newly 
formed and highly permeable angiogenic vessels, specifically those that lack perictye 
coverage, leaving the more pericyte covered blood vessels intact, or 2) FUSwMB 
activates microglia in and around the tumor vasculature, temporarily restoring BBB 
function. Regardless of its mechanism, the decrease in edema is an important favorable 
response in the treatment of brain tumors.  
Although directly quantifying edema is difficult, the combination of dynamic imaging 
and tracer kinetic modeling have previously been used to calculate surrogate measures of 
edema, often with radioactive water-based tracers or with perfusion MRI (16,17). In a 
standard two-compartment model, the extravascular distribution volume (Ve) is defined 
as the ratio of the forward volume transfer of contrast from plasma to tissue, Ktrans, to the 
back flux rate constant from tissue to plasma, Kep. In a distributed parameter model, such 
as the Johnson-Wilson and Lee model (18), Ve can be derived from the flow scaled 
impulse residue function, R(t), as the ratio of the flow-extraction product (FE) to the 
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backflux rate constant of extravasated contrast into the vascular space, k2. The use of a 
diffusible tracer that mimics water exchange across the BTB gives greater confidence that 
the measured tracer parameters can be used as a surrogate of edematous fluid distribution 
(19).  
Isovue is a diffusible CT contrast agent that is commonly used to quantify various 
perfusion parameters, such as PS, cerebral blood flow and cerebral blood volume, but can 
also be used to calculate the extravascular contrast distribution volume, Ve. Therefore, the 
purpose of this study is to use CT Perfusion or dynamic contrast-enhanced computed 
tomography (DCE-CT), corroborated by MRI T1 mapping and T2 fluid attenuation 
inverse recovery (FLAIR) imaging, to quantitatively evaluate the decrease in vasogenic 
edema following FUSwMB, and to use histology and immunuhistochemical staining to 
investigate the mechanisms responsible for this decrease in a C6 rat glioma model. 
4.2 Methods and Materials 
4.2.1 Animal Groups 
All experiments were approved by the Animal Use Subcommittee of the Canadian 
Council on Animal Care at our institution. Seventeen male Wistar rats (300-450g) were 
used in this study. For each rat, 1x106 C6 glioma cells were surgically implanted into the 
right striatum of the brain, using a stereotactic frame, with coordinates 3 mm to the right, 
and 1 mm posterior to the center of the bregma, along the coronal suture. Follow-up CT 
Perfusion scanning was performed at day 7 post implant, and every 2 days after that, until 
the following criteria were met: 1) the tumor was greater than 3 mm in diameter, 
measured using the average CT map (derived by averaging all images of the same slice in 
the CT Perfusion study), and 2) the tumor PS was greater than 1 ml/min/100g, typically 
at 8-15 days after implantation at which time the tumors underwent FUSwMB.  Prior to 
sonication, anesthesia was induced by breathing 2.5% isoflurane from a nose cone, before 
the head was shaved and depilated, and a tail vein catheter was inserted. Ketamine-
xylazine (10:1) was then administered at a rate of 5-10 ml/hr via the tail vein catheter as 
isofluorane was turned off. A baseline CT Perfusion scan was performed 20 minutes after 
switching the isofluorane off, after which the rat was placed on the FUS system inside the 
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CT gantry and the tumor was FUS sonicated under CT image guidance. The animals 
were divided into 2 groups: 1) An imaging group to evaluate changes in extravascular 
distribution volume (Ve), for which CT Perfusion was performed at baseline, 24, and 72 h 
post (n=10), and included a subgroup that underwent MRI at each time point (n=4), and 
2) a histopathology group to investigate histological changes in the vasculature before 
and after FUSwMB (n=7) which consisted of a subgroup that was sacrificed following 
baseline imaging without FUSwMB (n=3) and a subgroup that underwent FUSwMB and 
was sacrificed after follow-up imaging at 24 hours (n=4). 
4.2.2 Focused Ultrasound Sonication and Microbubble 
Administration  
The rat was placed supine on the FUS system (FUS Instruments Inc., Toronto, Canada) 
and was carefully positioned for optimal trans-cranial sonication, with the ultrasound 
(US) transducer placed orthogonally to the surface of the rat’s head.  Before the 
placement of the transducer, a layer of ultrasound gel was placed on the surface of the 
skull to allow for smooth US transmission from water in the FUS system to the scalp. A 
schematic of the experimental setup is shown in Figure 3-1. With the rat on the FUS 
system, an axial CT scan (140 kVp, 200 mA, 1s rotation time, 2.5 mm slice thickness) 
was performed to locate the brain followed by a baseline CT Perfusion study (see below 
for details) to locate the center of the tumor. These coordinates were then input into the 
FUS system to target the tumor center. All sonications were pulsed at 1 Hz, 0.5 W and a 
10 ms burst length (1 % duty cycle) for 120 s. A single bolus of Definity (Lantheus 
Medical Imaging, USA) microbubbles in 1:10 saline dilution at a dose of 20 µl/kg was 
manually injected via the vein catheter simultaneous with the start of sonication. 
4.2.3 CT Perfusion Study Protocol 
To quantitatively evaluate the BBB PS and other CT Perfusion derived parameters 
including the extravascular contrast distribution volume (Ve), a two-phase scanning 
protocol was used (First phase: two images per second acquired continuously for 30s 
using 80 kV, 250 mA, 0.5s rotation time, 2.5 mm slice thickness; Second phase: one 
image acquired every 15s for another 180 seconds using the same scanning parameters). 
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A 2.5 ml/kg bolus of 300 mg Iodine/ml (Isovue-300, 760 Da molecular weight) was 
intravenously infused via the tail vein catheter over 5 seconds at the start of the first 
phase. 
4.2.4 Tracer Kinetic Modeling  
The Johnson-Wilson-Lee (JWL) distributed parameter model (20,21), was used to model 
the distribution of injected contrast in the brain (tumor) using PS, cerebral blood flow 
(CBF) and cerebral blood volume (CBV) as the model parameters. The technique is 
explained in detail in Chapter 1 (section 1.9.4) of this thesis. One internal carotid artery 
was identified in the CT Perfusion images and a 2 x 2 pixel region was placed in the 
artery to generate the arterial time-density curve which was background subtracted to 
generate the arterial time-enhancement curve or the arterial input function, Ca(t) to JWL 
model. A typical arterial and the tumor time density curve from a rat study are shown in 
Figure 3-2.  
Under the assumption that brain blood flow (F or CBF) is constant and CT measured 
signal in artery and brain is linear with respect to the concentration of contrast, the brain 
time-enhancement curve, Q(t) is the product of F and the convolution of the arterial input 
function and the impulse residue function R(t), as shown in Equations 4-1 and 4-2. 
    𝑄 𝑡 = 𝐹 ∙ 𝐶! 𝑡 ∗ 𝑅 𝑡 − 𝑇!                                                                              … Equation 4-1 
        
𝑅 𝑡 = 1,         0 < 𝑡 ≤ !!!𝐸𝑒!!"!! !!!!! 𝐻(𝑡 − !!! ),         𝑡 > !!!                                     … Equation 4-2 
where T0 is the appearance time of contrast agent in the brain relative to that in the input 
artery, Vb (or CBV) is the volume of ‘flowing’ blood that is in large vessels, arterioles, 
capillaries, venules, and veins, Ve is the contrast distribution volume in the extravascular 
space, 𝐸 = 1− 𝑒!!"!  is the extraction fraction, or the fraction of contrast (mass) that is 
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transferred from the vascular to extravascular space during a single passage of blood 
from the arteriole end to the venous end of the capillaries in tissue (40), and H is the unit 
step function. As shown in Equation 4-2, R(t) of the JWL model is parameterized by F (or 
CBF), PS, Vb (or CBV), and Ve.  CT Perfusion 5 (a prototype of CT Perfusion 4D, GE 
Healthcare, Waukesha, Wis) was used to estimate and generate parametric maps of PS, 
CBF, CBV and Ve, by iteratively changing their values until an optimal fit to Q(t) is 
reached according to Equations 4-1 and 4-2 for each voxel. 
 
 
Figure 4-1: A schematic diagram for the blood flow (F) scaled impulse residue 
function, R(t), where E is extraction efficiency, T0 is the time for the contrast to 
appear, W is the mean transit time, and k2 is the rate constant that defines transfer 
from the interstitial space back into the vasculature.  
4.2.5 Magnetic Resonance Imaging 
A subgroup of the imaging group underwent MRI (3T Biograph mMR, Siemens 
Healthcare) immediately prior to CT Perfusion at baseline, 24-h, and 72-h post 
sonication, to image fluid accumulation surrounding the tumor. An axial T2-FLAIR 
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sequence (TI = 2500 ms, TE/TR = 94ms/9000ms, slice thickness = 3 mm, NEX = 4, 256 
x 256, FOV = 70mm) and a dual flip angle quantitative longitudinal relaxation time (T1) 
sequence (TR/TE = 15ms/3.31ms, flip angle 1 = 5°, flip angle 2 = 26°, slice thickness = 
3.00mm, NEX = 6, 256 x 256, FOX = 70 mm) were used to evaluate edema. T1 was 
calculated using the MAPIT software package (Siemens, Erlangen Germany).  
4.2.6 Imaging Analysis of CT Perfusion and MRI Study 
PS, CBF, and CBV map from the CT Perfusion study were used to delineate the tumor. A 
PS of over 1 ml/min/100g was used as the threshold for the tumor margin, as this value 
has previously been measured in high-grade brain tumors (22). Increased tumor CBF and 
CBV threshold of 1.5x relative to the contralateral hemisphere were also used to guide 
delineation of the tumor rim (23). The tumor ROI for each time point was delineated 
manually using the above thresholds on the corresponding PS, CBF and CBV map and 
used to calculate the mean tumor values. For MR image analysis, the T2- FLAIR image 
and T1 map were used to manually delineate the edematous ROI, which included tumor 
and peri-tumor space, at each time point.  
4.2.7 Calculation of Extravascular Distribution Volume 
The time-density curve from the tumor ROI after background subtraction, Q(t), was 
deconvolved with the corresponding arterial input function, Ca(t), to estimate PS, CBF, 
CBV and Ve, by iteratively changing their values until an optimal fit to Q(t) is reached 
according to Equations 4-1 and 4-2. Once the model fit is found, the parameters can be 
used to calculate the extravascular distribution volume, Ve: 
 𝑉! = !"!!                                                                                                                            … Equation 4-3 
where k2  is the backflux constant from interstitial space to intravascular space. A 
schematic diagram of the flow scaled R(t) for the JWL model is shown in Figure 4-1. 
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4.2.8 Immunohistochemistry 
For the histopathology analysis group, the animals were euthanized either prior to 
FUSwMB (n=3), or at 24-h post (n=4). Once euthanized, the animals were immediately 
perfusion-fixed with a phosphate buffered saline solution, followed by 4% 
paraformaldehyde. The brains were removed and fixed in 10% formalin for 24 hours, 
before they were cut into 3 mm thick blocks, paraffin-embedded, then sectioned at 5 µm. 
The sections were stained with monoclonal anti-CD31 antibodies (1:50, Acris 
Antibodies) for endothelial cells, as a marker for endothelial proliferation and 
angiogenesis, and anti- vimentin antibodies (1:100, Abcam), as a marker for pericyte 
expression (24), or glial activation (25). Light microscopy was used to evaluate CD31 
and vimentin expression. For CD31 analysis, the total number of intact and collapsed 
CD31 positive blood vessels, in 5 separate fields (20x) of the most vascular region of the 
tumor was recorded. Intact vessels were defined as having a CD31 stained rim around a 
blood vessel, whereas collapsed vessels were defined as circular regions with condensed 
CD31 expression in the center (26). For vimentin analysis, the average tumor staining 
density was scored as 1 (light – limited to single pericytes or glial cells), 2 (moderate – 
the appearance of light streaks/filament structures), and 3 (heavy – appearance of 
multiple heavy streak/filament structures) (27). 
4.2.9 Statistical Analysis 
The differences in CT Perfusion and MRI parameters between time points were assessed 
using Mann-Whitney U Tests, with Bonferroni correction applied to account for 3 
repeated measures (m=3), comparing baseline with 24 h and 72 h and 24 h with 72 h. 
Regression analysis was used to investigate the correlation between T2-FLAIR image 
signal intensity and quantitative T1 derived measures of edema with Ve, as measured by 
CT Perfusion at all time points. For immunohistochemical analysis, differences in the 
number of intact and collapsed CD31 vessels and vimentin scores between the sonicated 
and control groups were assessed using non-parametric t-tests. Statistical significance 
was determined as P < 0.05. All statistical analysis was performed with IBM SPSS v23.  
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4.3 Results 
Tumor CBF, CBV, Ve and Isovue PS over time (n=10) out to 72 hours following 
FUSwMB is shown in Figure 4-2. Tumor Isovue PS was significantly lower at 24 h post 
(6.3 ± 4.3 ml/min/100g; P < 0.01, significant after Bonferroni correction) compared to 
baseline (9.6 ± 6.6 ml/min/100g), but not compared to 72 h post sonication (8.1 ± 5.2 
ml/min/100g; P = 0.08). Similarly, Ve was significantly lower at 24 h post sonication (31 
± 22 ml/100g; P < 0.005, significant after Bonferroni correction), when compared to 
baseline (39 ± 26 ml/100g), but not compared to 72 h post sonication (35 ± 24 ml/100g, P 
= 0.2). Both CBF and CBV were higher at 24 h post (75 ± 30 mL/min/100g and 4.4 ± 1.3 
mL/100g; both P < 0.03 not significant after Bonferroni correction) compared to baseline 
(62 ± 19 mL/min/1000g and 3.8 ± 0.8 mL/100g), but not compared to 72 h post 
sonication (69 ± 26 mL/min/100g, P = 0.07 and 3.9 ± 1.0 mL/100g; P = 0.2, 
respectively).  
Tumor T1 and T2-FLAIR SI over time for the subgroup that underwent MRI (n=4) in 
addition to CT Perfusion imaging is shown in Figure 4-3. The tumor T1 was lower at 24 
h post (1753 ± 153 ms; P < 0.05 but not significant after Bonferroni correction) compared 
to baseline (1807 ± 184 ms) but not compared to 72 h post sonication (1847 ± 253 ms; P 
= 0.2). There were no significant changes in T2-FLAIR SI at 24 h post (662 ± 61; P = 
0.2) or 72 h post (704 ± 192; P = 0.4), compared to baseline (688 ± 95). 
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Figure 4-2: Serial tumor PS, extravascular contrast distribution volume (Ve), 
cerebral blood flow (CBF), and cerebral blood volume (CBV), measured using 
Isovue (760 Da) contrast agent, out to 72 hours following FUSwMB (n=10). 
*Significantly different from baseline value as determined by Bonferroni corrected 
non-parametric t-tests. 
CT Perfusion derived PS maps, MRI T1 maps and T2-FLAIR images for a rat before and 
after FUSwMB are shown in Figure 4-4. When compared with Ve, both the T1 (R2 = 
0.52, m = 5.4; P < 0.02) and the FLAIR SI (R2 = 0.85, m = 4.9; P < 0.005) showed 
moderate to strong correlations as shown in Figure 4-5.  
 
 Figure 4-3: Serial tumor longitudinal relaxation time (T1) and fluid attenuated 
inversion recovery (FLAIR) signal intensity (SI) out to 72 hours following FUSwMB 
(n=4).  
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Figure 4-4: CT Perfusion derived Isovue PS maps, and MRI longitudinal relaxation 
time (T1), and fluid attenuated inverted recovery (FLAIR) maps for a rat following 
FUSwMB. 
 
Figure 4-5: Correlation of CT Perfusion derived extravascular distribution volume 
(Ve) with MRI longitudinal relaxation time (T1), and fluid attenuated inverted 
recovery (FLAIR) signal intensity (SI) in 4 rats at baseline, 24 hr, and 72 hr post 
sonication. 
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A box plot quantifying the number of collapsed and intact CD31 expressing vessels in the 
sonicated and control group is shown in Figure 4-6. Comparing the tumor vasculature 
before (control group) and at 24 h following FUSwMB revealed that the total number of 
CD31 expressing collapsed vessels in the sonicated group (9 ± 2; p < 0.01) was 
significantly greater than control (2 ± 1). For the control group, the total number of CD31 
expressing intact vessels (7 ± 1; p < 0.02) was also significantly greater than the number 
of collapsed vessels (2 ± 1), whereas there was no difference between intact (5 ± 2; p = 
0.1) and collapsed vessels (9 ± 2) in the sonicated group. The average vimentin 
expression score was significantly higher in the sonicated group (2.5 ± 0.6; p < 0.05) 
compared to the control group (1.3 ± 0.6). Representative regions from the CD31 and 
vimentin stained sections are presented for the sonicated and control groups in Figure 4-
7. 
4.4 Discussion 
The purpose of this study was two-fold: 1) Use CT Perfusion and MRI to investigate the 
change in vasogenic edema resulting from the decrease in BTB PS to small molecules up 
to 72 hours following FUSwMB, and 2) use immunohistochemistry to investigate the 
histopathology that contributes to the observed tumor response.  
 
121 
 
Figure 4-6: Boxplots of the total number of intact and collapsed CD31 expressing 
vessels for all 5 fields in the sonicated (r=4) and control (r=3) groups. #Significantly 
different than the control group, P < 0.05. *Significant difference between the 
number of intact and collapsed CD31 expressing vessels, P < 0.05.  
In Chapter 3 of this thesis, we reported on the decrease in BTB PS up to 72 hours 
following FUSwMB, using a small (760 Da) diffusible CT contrast agent. As discussed 
in Chapter 1, Ve is the extravascular contrast distribution volume in tissue or it is the 
surrogate marker of vasogenic edema. In this study, we found that the CT Perfusion 
derived Ve was significantly lower at 24 h post sonication, the time-point at which the 
measured BTB PS was also the lowest. It has been previously reported that both T1 and 
T2 values from proton MRI can be used as surrogates of vasogenic brain edema, in pre-
clinical and clinical cases (28,29). Our MRI subgroup demonstrated that quantitative T1 
measured with dual flip angles at 24 h post was lower than baseline although this 
difference was not significant. However, T2-FLAIR signal did not show any significant 
decrease from baseline at any of the time-points. CT Perfusion derived Ve showed 
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moderate to strong correlation with both the quantitative T1 (R2 = 0.52) andT2- FLAIR 
SI (R2 = 0.85), implying that it can be used as a surrogate of vasogenic brain edema.  
 
Figure 4-7: Representative immunohistochemical stained tumor regions showing 
intact (hollow arrow) and collapsed (filled arrow) CD31 expressing vessels, as well 
as vimentin expression score, in the sonicated (n=4) and control groups (n=3). The 
representative vimentin expression shown was scored as 3 in the sonicated group, 
and as 1 in the control group.  
Another interesting finding from this study is that both CT Perfusion derived CBF and 
CBV show an increasing trend at 24 h post, at the time-point when both the tumor PS and 
vasogenic edema were at their lowest. This effect is similar to the ‘normalization’ anti-
tumor effect that has been associated with anti-angiogenic therapies such as bevacizumab 
(30). These findings highlight the potential of combining anti-angiogenic therapies and 
FUSwMB, conferring a synergistic effect that decreases edema from reduced tumor PS 
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while normalizing the vasculature to increase blood flow and hence drug delivery. Not 
only would this lessen the neurological symptoms resulting from vasogenic edema in the 
brain, but may also increase the delivery of larger molecules that are unable to passively 
diffuse across the BTB, and must rely on the transvascular pressure gradient driven 
convective transport to get into the tumor, as discussed in chapter 3 of this thesis. 
The goal in the second part of this study was to use immunohistochemical staining to 
investigate the histopathology behind the decreased PS and vasogenic edema within the 
tumor. An anti-CD31 stain was used to evaluate the number of intact and collapsed 
microvessels within the most vascular region of the tumor, to quantify the vascular 
density and damage before and at 24 h following FUSwMB. In the untreated control 
tumors, there was significantly greater number of intact vessels than collapsed vessels, of 
the latter there were almost none. At 24 h following FUSwMB, there was a significant 
increase in the number of collapsed vessels when compared to the untreated control. 
These results suggest that FUSwMB using the exposure parameters optimized to induce 
transient BBB opening with minimal vascular injury (have to reference your first paper 
here), may be used to selectively target and destroy newly formed angiogeneic vessels, 
which lack functional perictye coverage and are more susceptible to damage. In GBM, 
the newly formed angiogeneic vessels contribute to the increased PS, the destruction of 
which would lead to the decrease in PS measured with CT Perfusion. 
An anti-vimentin stain was also used to assess pericyte coverage and/or glial expression 
before and at 24 h following sonication. Vimentin is an intermediate filament protein that 
plays a key cytoskeletal role, and has been previously shown to correspond with glial 
fibrillary acidic protein (GFAP) expression in the central nervous system (CNS) (31). 
One of the important functions of glial cells is to regulate BBB function through its 
vascular-encircling end feet (32). In response to many CNS pathologies, such as stroke, 
trauma, or tumor growth, a structural and functional astrocytic response called ‘reactive 
gliosis’ is able to partially restore BBB function (33). Studies using a genetic mouse 
model determined that in the absence of intermediate filament proteins, such as vimentin 
or GFAP, reactive gliosis is attenuated with distinct pathophysiological and clinical 
consequences (34), indicating that the BBB regulatory function of glial cells is dependent 
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on the expression of these proteins. Our immunohistochemical results found that tumors 
at 24 h following sonication displayed moderate to heavy vimentin expression, whereas 
untreated control tumors displayed only light to moderate vimentin expression, 
suggesting the possibility of some form of reactive gliosis that developed following 
FUSwMB, decreasing BTB permeability, and the associated vasogenic edema. It is 
important to consider that the procedure used to score vimentin did not discriminate 
between the two features of vimentin expression – perictye coverage or activated glial 
cells. As such, the increased vimentin expression at 24 h following sonication may be 
attributed to the increased perictye expression or activation of glial cells. Further co-
expression studies are required to evaluate the changes in pericyte and/or activated glial 
following sonication, along with vimentin staining. 
There are limitations of this study to be considered. First, CT Perfusion derived Ve, 
measured with a small (760 Da) diffusible iodinated contrast agent and a relatively short 
acquisition time of 3.5 min, may not reflect the true water Ve as a surrogate of vasogenic 
edema. However, we did find Ve correlated well with MRI T1 and T2, which have 
previously been shown to measure water content and vasogenic edema (35). The second 
limitation was using immunohistochemical staining to investigate the histopathologic 
basis behind the observed decrease in BTB permeability and vasogenic edema, 
particularly with the correlation of immunohistochemical findings with imaging results. 
Brain tumors, particularly GBM, can be highly heterogeneous due to the presence of 
multiple cell types in the microscopic scale, whereas CT Perfusion derived measures of 
permeability and vasogenic edema were performed at a much larger spatial scale, making 
it difficult to compare immunohistochemical staining and imaging results. 
4.5 Conclusion 
In this study, we used CT Perfusion to derive the extravascular distribution volume (Ve) 
as a surrogate of vasogenic edema in a pre-clinical C6 rat glioma model. We found that 
Ve was significantly lower at 24 h post sonication, the time at which BTB PS was also at 
its lowest. CT Perfusion derived Ve showed moderate to strong correlations with MRI T1 
and T2 measurements, which have previously been shown to correlate with the extent of 
vasogenic edema in brain tumors, indicating it may be used as a reliable surrogate of 
125 
vasogenic edema in brain tumors. In addition, immunohistochemical staining of vascular 
and glial markers suggests the destruction of newly formed and angiogenic blood vessel 
and/or the increased glial expression resulting from intermediate filament driven reactive 
gliosis, may be responsible for the decrease in PS and vasogenic edema following 
FUSwMB. 
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Chapter 5  
5 Conclusion and Future Work 
5.1 Summary of Findings 
This thesis demonstrated: 1) the feasibility of using CT Perfusion to monitor blood-brain 
barrier and brain tumor barrier (BBB/BTB) permeability surface product (PS) in normal 
intact brain and brain tumor respectively following FUS sonication with MB 
administration (FUSwMB); 2) in a C6-glioma brain tumor model in rats, instead of a 
transient increase in PS as seen in normal brain, a decrease in PS acutely and at 24 hours 
following FUSwMB; 3) correlation of the observations in 2) with decrease in vasogenic 
edema corroborated by tissue water imaging with MR and with pruning of immature 
leaky blood vessels and reactive gliosis as shown by histopathology. 
5.1.1 CT Perfusion to quantify PS changes following FUSwMB 
Prior to the work presented in this thesis, there were only a handful of pre-clinical studies 
that attempted to use tracer kinetic analysis to quantify endothelial PS following 
FUSwMB, using either Gd-enhanced T1 MRI (1,2), or SPECT (3).  
For dynamic contrast enhanced studies, CT has the following advantages over MRI: 1) 
Greater temporal resolution with sub-millimeter spatial resolution, 2) better quantitative 
accuracy as x-ray attenuation is less affected by the tumor microenvironment (4), and 3) 
less susceptibility to contrast signal saturation from repeated scans (5).  
In Chapter 2 of this thesis, we presented a range of FUSwMB parameters that can induce 
transient BBB opening in a normal rabbit brain, with minimal damage to neurons and 
vasculature, monitored with CT Perfusion derived BBB PS. Furthermore, measured PS 
time profiles post FUSwMB allow for visualization of the distinct window for increased 
therapeutic drug delivery, and provide a method for quantifying and monitoring the 
extent of drug delivery in a clinical setting.  
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5.1.2 BTB PS response following FUSwMB 
Previous pre-clinical brain tumor studies have attempted to quantify the tumor 
permeability to various molecules following FUSwMB (6–11). The few studies that have 
attempted to characterize BTB PS found an increase in the parameter and/or drug 
delivery following sonication, although the results varied because of the stage (early or 
late) at which the tumor is sonicated, and the time delay following sonication at which PS 
or delivery was evaluated (6,10). 
In Chapter 3 of this thesis, we demonstrated that although there was a transient increase 
in BTB small molecule PS immediately following FUSwMB, this is followed by a 
decrease in PS at 24 hours post, particularly in underdeveloped and less permeable 
tumors. However, when a larger contrast molecule was used, there was a trend of 
increasing PS following FUSwMB, although this was not significant after correction for 
multiple comparison. This surprising result was rationalized by the physical destruction 
of newly formed and highly permeable angiogenic vessels which lack pericyte coverage 
and/or the stimulation of microglia in and around the tumor vasculature, highlighting the 
potential for FUSwMB to manipulate the tumor vasculature and its microenvironment, 
beyond simply opening the BTB. Furthermore, the decrease in Isovue PS between 24-72 
hrs following FUSwMB may be accompanied by a decrease in edema as corroborated by 
tissue water imaging with MR, and interstitial fluid pressure (IFP), thereby increasing PS 
and accumulation of larger chemotherapeutic agents, such as bevacizumab, that are 
unable to passively diffuse across the BTB and must rely on convective bulk solute flow.  
In the context of drug delivery, the volume transfer constant Ktrans (FE), which is 
estimated by the Johnson and Wilson (JW) model and encapsulate the influence of blood 
flow relative to PS, is more appropriate for drug delivery than PS alone. Unlike the 
normal brain, where drug delivery across the disrupted BBB is diffusion limited and FE 
can be approximated by PS, this condition is not necessarily true in brain tumors, where 
the PS may be significantly elevated relative to blood flow, in which case FE would be a 
more appropriate functional parameter to quantify transvascular drug delivery, 
particularly for larger drugs that rely on convective solute flux, instead of diffusion. 
Further investigation is required to determine whether PS or FE is the correct functional 
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parameter to use and under which conditions, when measuring drug delivery across the 
BTB. 
In Chapter 4 of this thesis, we showed that this decrease in BTB PS, as measured with a 
small molecule CT contrast agent Isovue, was accompanied by a decrease in the 
extravascular distribution volume, Ve, a surrogate of vasogenic edema. The implication 
of this finding is that FUSwMB may be used to temporarily alleviate the IFP that results 
from vasogenic edema in brain tumors, as well as increase the delivery of molecules 
across the BTB, particularly larger antibody-like molecules such as bevacizumab, that 
rely on convective transport to accumulate in the tumor. In addition, 
immunohistochemical staining of vascular and glial markers suggest the destruction of 
immature leaky blood vessel, and/or the increased glial expression, as a form of 
intermediate filament driven reactive gliosis, may be responsible for the decrease in PS 
and vasogenic edema following FUSwMB in brain tumors. 
5.2 Future Work 
The work presented in this thesis used CT Perfusion measured PS to address questions 
regarding the use of FUSwMB to increase drug delivery of blood borne solutes across 
intact BBB in normal brain and across the BTB in a rat C6 tumor model. Our findings in 
brain tumor led us to conclude that although the BTB may increase hours following 
sonication, it is proceeded by a decrease in PS, and therefore vasogenic edema. This 
seemingly contradictory result has generated a number of new and important questions 
that future investigation can address.  
5.2.1 Evaluating the increase in PET-labeled Bevacizumab delivery 
following FUSwMB in a C6 Rat Tumor Model 
One of the significant findings of this thesis was the decrease in BTB PS, measured using 
a standard small molecule CT contrast agent, at 24 hours following FUSwMB. To our 
knowledge, this is a previously unreported result, and generates a number of questions. In 
the context of blood borne solute drug delivery, a decrease in measured BTB PS is not 
beneficial. However, the decrease in BTB PS was also accompanied by a decrease in 
vasogenic edema, which we hypothesize would restore the transvascular pressure 
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gradient required for the delivery of larger molecules, such as bevacizumab, that are 
reliant on convective transport across the BTB. Radiolabeled PET tracers are commonly 
used to evaluate drug delivery and accumulation in tumors. Recently, bevacizumab has 
been tagged with 89Zr in a number of studies looking at its delivery and distribution in 
tumors (12–16). A future study using 89Zr labeled bevacizumab would allow us to 
evaluate the improved delivery that results from a decrease in BTB PS, as measured by a 
diffusible small molecule CT tracer post FUSwMB in a C6 brain tumor model.  
5.2.2 Improvement in clinical outcomes following FUSwMB in 
combination with Bevacizumab administration in a C6 Rat 
Glioma Model 
In a healthy brain, pro- and anti- angiogenic signaling molecules are balanced and able to 
maintain an organized and efficient vascular supply. In brain tumors, the overexpression 
of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF) results in a 
permeable BTB, increased IFP, and therefore vasogenic edema. Gliomas, which account 
for approximately 70% of all malignant brain tumors, demonstrate particularly poor 
prognosis due in part to the vasogenic edema that results from the breakdown in the BTB 
(17). Furthermore, this breakdown in BTB is also accompanied by an increase in IFP 
(18), which creates a barrier for transvascular drug delivery, increases hypoxia induced 
treatment resistance within and surrounding the tumor, and promotes micrometastasis 
surrounding the primary tumor that serve as sites of recurrence (19).  
In Chapter 4 of this thesis, we showed that the decrease in BTB PS following FUSwMB, 
as measured with a standard small molecule CT contrast agent, was also accompanied by 
a decrease in extravascular distribution volume, Ve, which is a surrogate of vasogenic 
edema. It can be hypothesized that this decrease in vasogenic edema following FUSwMB 
is also accompanied by a decrease in IFP in and around the tumor mass – leading to a 
‘vascular normalization’ effect that has been associated with anti-angiogenic therapies 
such as bevacizumab (20–22). The destruction of newly formed pro-angiogenic vessels or 
the stimulation of reactive glial cells following FUSwMB would normalize the BTB 
permeability, lowering the surrounding IFP and improving perfusion throughout the 
tumor. Not only would this benefit the neurological symptoms that result from vasogenic 
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edema in the brain, but should also increase the delivery of larger molecules that rely on 
the transvascular pressure gradient driven convective transport across the BTB, as 
discussed in chapter 3 of this thesis. A future study looking at the improvement in clinical 
outcomes, particularly survival, from increased bevacizumab delivery following 
FUSwMB, in a C6 Rat Glioma Model would allow for the investigation of this 
synergistic benefit.  
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